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Molecular chaperones are a class of conserved proteins that maintain proteostasis within all 
organisms. In order to carry out this task, chaperones bind to unfolded protein substrates 
and support outcomes such as folding, localization, complex assembly, aggregation 
prevention, and degradation. The diversity of chaperones reflects the diversity of functions 
they carry out within the cell. One chaperone, 70-kDa heat shock protein (Hsp70), is 
ubiquitously expressed and acts as a coordinating hub for a large network of co-chaperones, 
including J proteins, nucleotide exchange factors (NEFs), and tetratricopeptide-repeat 
(TPR) domain-containing proteins. The complexity of this network has posed challenges to 
fully understanding its many roles in cellular health and how these roles may fail in diseases 
of protein misfolding, such as Alzheimer’s disease (AD). We have attempted to gain a more 
detailed understanding of these networks and the cooperation and competition that occurs 
within them by using techniques that allow us to probe the function of many chaperones in 
parallel. Using chemical genetics, we have investigated the functional roles of individual J 
proteins in Saccharomyces cerevisiae. We found that many J proteins have distinct roles in 
supporting certain cellular functions that cannot be compensated for by endogenous levels 
of other J proteins. We also designed peptide microarrays composed of peptides derived 
from the sequences of two model chaperone substrates, luciferase and tau. The human J 
protein, DNAJA2, is able to support Hsp70-mediated refolding of luciferase in vitro, while a 
highly homologous J protein, DNAJA1, is not. Binding experiments using the luciferase 
microarrays demonstrate that Hsp70 simulates the binding of DNAJA2, but not DNAJA1, 
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to a β-sheet between the domains of luciferase, suggesting that increased affinity for this 
binding site during luciferase refolding may be the mechanistic basis of the divergent folding 
abilities of these two J proteins. We also mapped the binding of 17 chaperones to tau, a 
protein that misfolds into amyloid fibrils in a class of neurodegenerative diseases called 
tauopathies, including AD. We find that chaperones generally bind a set of “hotspots” on 
tau, many of which are rich in residues known to be phosphorylated in AD tau or sites of 
mutations linked to other tauopathies. These results suggest that chaperones compete with 
one another and other tau binding partners, like kinases and phosphatases, to direct the 
metabolism of this protein in both healthy and diseased systems. Finally, we designed a 
peptide microarray to test the hypothesis that chaperones might preferentially bind 
amyloidogenic sequences in order to prevent the formation of toxic amyloid fibrils. Using 
this array we demonstrated that some chaperones, including Hsp70 and a subset of J 
proteins, have a slight but consistent preference to bind amyloid-forming peptides over 
normal ones. In subsequent solution-phase binding assays, we confirm this finding but also 
conclude that other peptide properties contribute strongly to Hsp70 binding. Taken together, 
these studies advance our understanding of chaperone networks and suggest novel future 







The Hsp70 Multi-Protein Complex as a Drug Target 
1.1 Abstract 
Heat shock protein 70 (Hsp70) is a molecular chaperone that plays critical roles in protein 
homeostasis (proteostasis). Using cycles of ATP hydrolysis, Hsp70 binds to unfolded 
proteins and favors their folding. Additionally, if the protein is damaged, Hsp70 directs it to 
the proteasome for disposal. Thus, Hsp70 has emerged as a drug target in protein misfolding 
diseases, such as neurodegenerative disorders. However, competitive inhibitors of ATP 
binding have proven challenging to discover and, in some cases, this strategy may not be the 
best way to redirect Hsp70 function. Another approach is to inhibit Hsp70’s interactions 
with important co-chaperones, such as J proteins, nucleotide exchange factors (NEFs) and 
tetratricopeptide repeat (TPR) domain proteins. These co-chaperones bind Hsp70 and are 
critical in guiding its chaperone activities, such as the selection of substrates and dictating 
their ultimate fate. For example, J proteins are a potentially attractive target because they 
help choose substrates for Hsp70. Thus, pharmacologically regulating the assembly or 
disassembly of Hsp70 complexes might be a powerful way to re-shape the proteome and, 
potentially, restore healthy proteostasis. By considering the Hsp70 complex as a composite, 
multi-protein drug target, we might not only develop new leads for therapeutic development 





1.2.1 Diversity of Hsp70 Functions 
Heat shock protein 70 (Hsp70) is a molecular chaperone that plays a central role in protein 
quality control [1, 2]. Hsp70 binds to protein substrates to assist with their folding [3, 4], 
degradation [5-7], transport [8], regulation [9, 10] and aggregation prevention [11]. The 
capacity of Hsp70 to carry out these widely divergent functions arises, in part, from three 
features. First, evolution has given rise to multiple homologous Hsp70 genes [12, 13]. These 
Hsp70s populate all of the major subcellular compartments. For example, the cytosol of 
human cells has two major isoforms of Hsp70, a stress-inducible form (Hsp72/HSP1A1) 
and a constitutive form (Hsc70/HSPA8). Similarly, BiP (HSPA5) is the form in the 
endoplasmic reticulum and mortalin (HSPA9) in the mitochondria. For the purposes of this 
thesis, “Hsp70” will often be used to broadly refer to these chaperones because they are 
thought to, in many cases, have similar biochemical properties. Another source of 
functional diversity in Hsp70s is cooperation with other chaperones, such as Hsp90 or 
Hsp60 [4]. Cooperation between Hsp70 and Hsp90, for example, is critical to the function 
of nuclear hormone receptors [8]. Finally, the full diversity of Hsp70 activities is achieved 
through cooperation with a large network of co-chaperones [1, 14], including J proteins, 
nucleotide exchange factors (NEFs), and tetratricopeptide repeat (TPR)-domain containing 
proteins [15]. These factors bind to Hsp70 and guide its many chaperone activities. In 
addition, each class of co-chaperones includes many distinct examples in mammalian cells, 





1.2.2 Hsp70 as a therapeutic target 
Hsp70 has been implicated in multiple diseases, such as neurodegenerative disorders [16], 
cancer [17], and infectious disease [18]. The evidence linking Hsp70 to disease has been 
recently reviewed [19-21]. Despite this strong connection, relatively little progress has been 
made in bringing Hsp70-targeted molecules to the clinic, with only two inhibitors having 
been explored in clinical trials [22, 23]. One of the contributing factors to this lack of 
translational progress is that Hsp70’s functional promiscuity makes it difficult to predict 
potential off-target effects. As discussed above, Hsp70 is involved in many key processes in 
the cell; thus, it isn’t clear how therapeutics could be used to re-balance some pathological 
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Hsp70 functions without impacting global proteostasis. One attractive possibility may be to 
target the interactions between Hsp70 and its co-chaperones, because these factors are 
thought to diversify Hsp70’s functions. 
 
This chapter explores the structure and function of Hsp70 multi-protein complexes and 
evaluates recent progress in identifying compounds that selectively target the 
assembly/disassembly of these complexes. The underlying model is that each complex 
composed of an Hsp70 (e.g. Hsc70, Bip, etc) bound to a specific set of co-chaperones (e.g. J 
protein, NEF, TPR, etc) might be involved in a discrete aspect of chaperone biology (e.g. 
protein folding, degradation, clathrin uncoating, etc.). Thus, if small molecules selectively 
disrupted an interaction between Hsp70 and a specific co-chaperone, then only a subset of 
Hsp70 biology might be impacted. In other words, the complexity of this chaperone 
network provides a unique opportunity to influence specific subsets of protein quality 
control while leaving the rest unperturbed. The challenge is that it has been notoriously 
difficult to target protein-protein interactions [24-26], such as those between Hsp70 and its 
co-chaperones. However, new advances in high throughput screening (HTS) methodology 
are rapidly changing the landscape of discovery in this area. In fact, Hsp70 might be a 
particularly attractive target for deploying these methods, owing to its high number of 
protein-protein contacts and the importance of these interactions in guiding Hsp70 biology. 
 
1.3 Structure and function of Hsp70 and its complexes 
Hsp70 consists of two domains, a 45 kDa N-terminal nucleotide binding domain (NBD) 
and a 25 kDa C-terminal substrate-binding domain (SBD) connected by a short flexible 
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linker [27]. The NBD of Hsp70 is further divided into two subdomains, lobes I and II, that 
are each divided into an “A” and “B” region (Figure 1.2). These lobes form a cleft that 
binds ATP with a nucleotide-binding cassette that is related to hexokinase and actin [28]. 
Hsp70’s SBD is also composed of a 15 kDa β-sandwich subdomain with a hydrophobic 
groove for polypeptide binding and a 10 kDa α-helical region which forms a “lid” over the 
polypeptide-binding site [29]. Hsp70 preferentially binds hydrophobic regions of proteins 
and can therefore bind newly synthesized linear peptides or exposed regions on partially 
unfolded proteins [3, 30]. The lack of strong sequence specificity allows Hsp70 to bind a 
variety of client proteins including signal transduction proteins, clathrin, nuclear hormone 
receptors, and cytoskeletal proteins [31, 32]. 
 
1.3.1 ATPase cycle of Hsp70 
The ATPase cycle of Hsp70s has been largely studied for the prokaryotic DnaK. In this 
chaperone, ATP hydrolysis controls allostery between the NBD and SBD. In the ATP-
bound state, Hsp70 has a low affinity for substrate and retains an “open” substrate-binding 
cleft, but conversion to the ADP-bound state causes the α-helical lid region to close (Figure 
1.2) [33]. In DnaK, this crosstalk between the NBD and SBD appears to be bidirectional, 
because substrate binding also promotes nucleotide hydrolysis [33, 34]. Thus, ATP 
hydrolysis in Hsp70s is thought to be a major determinant of their chaperone functions. For 
example, mutations in the ATP-binding cassette have dramatic effects on chaperone 
functions in vitro and in vivo [35]. However, recent mutagenesis studies have further shown 






example, some mutations in DnaK that dramatically reduce ATP turnover have only 
modest effects on luciferase refolding. These observations suggest that inhibiting the ATPase 
activity of Hsp70 might not always directly lead to proportional changes in functional 
outcomes, such as reduced client stability. Rather, modifying the interactions with co-
chaperones might have a more predictable effect on chaperone functions [35]. 
 
1.3.2 Co-chaperones regulate Hsp70 structure and activity 
The major families of co-chaperones bind to distinct interaction surfaces on Hsp70. The J 
protein co-chaperones bind Hsp70 at lobe IIA of the NBD and accelerate the rate of ATP 
hydrolysis [36]. The NEF co-chaperones bind lobes IB and IIB of Hsp70’s NBD and 
facilitate the release of ADP, which has also been shown to accelerate Hsp70’s ATPase rate 
[37]. TPR domain containing co-chaperones bind Hsp70’s C-terminus and have been shown 
to modulate the fates of Hsp70 client proteins [38]. Thus, the major families of co-
chaperones bind Hsp70 to regulate its enzymatic activity, its localization and its choice of 
substrates. 
 
1.4 Approaches to targeting Hsp70 
1.4.1 Competitive nucleotide analogues 
What is the best way to chemically target Hsp70? One possible approach is to inhibit 
ATPase activity with competitive nucleotide analogs, as has been done with Hsp90 
inhibitors [39]. The nucleotide-binding cleft of Hsp70 is well defined and relatively deep, 
suggesting that it might be suitable for development of inhibitors. However, Hsp70 has a 
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tight affinity (mid-nanomolar) for nucleotide, 300-fold better affinity than Hsp90 [40-43]. 
Because the cellular concentration of ATP is typically about 1-5 mM, protein targets with a 
tight affinity for ADP and ATP are much more difficult to inhibit than those with a weaker 
affinity. Further, the ATP-binding cassette in Hsp70 is highly homologous in actin and 
other abundant proteins. Thus, selectivity for the chaperone might be challenging. Despite 
these challenges, innovative work performed by a group at Vernalis has produced 
competitive, orthosteric inhibitors of Hsp70, using structure-based design [44]. Consistent 
with their design, these compounds inhibit cancer cell viability [44] and this group has even 
been successful at selectively targeting BiP [45]. However, Massey has reported that the path 
towards orthostatic, competitive inhibitors of Hsp70 is quantitatively more challenging than 
the parallel path to other related targets, such as Hsp90 [43]. Given these hurdles, it seems 
prudent to pursue additional routes to the design and discovery of potent and selective small 
molecule modulators targeting Hsp70.  
 
1.4.2 Inhibitors of substrate binding 
Targeting the substrate-binding cleft of Hsp70 is the next logical avenue, given the depth of 
the site and its known affinity for relatively low molecular mass peptides. This approach has 
been taken by Chaperone Technologies in their development of antibiotics. For example, a 
series of 18-20 amino acid peptides, including drosocin, pyrrhocoricin, and apidaecin, are 
known to interact with DnaK [18]. Of these peptides, pyrrhocoricin exhibited broad-
spectrum antibacterial activity. Competition experiments indicated that this peptide has two 
binding sites on DnaK, one of which is thought to be adjacent to the substrate-binding 
pocket. Interestingly, pyrrhocoricin has activity against bacteria but not mammalian cells 
 
 9 
[46], suggesting that the SBD could be leveraged to gain selectivity between different 
isoforms of Hsp70. While this work highlights the usefulness of SBD-targeted compounds as 
antibiotics, it is unclear whether this strategy could be implemented in the development of 
therapeutics for different Hsp70 related diseases.  
 
1.4.3 Targeting co-chaperones and their interactions with Hsp70 
Given the significant challenges associated with the targeting of either the nucleotide- or 
substrate-binding regions of Hsp70, additional strategies are worth pursuing. A number of 
additional Hsp70 inhibitors have been identified, but their mechanisms are not known yet 
[47-49]. To supplement this collection of compounds, targeting the PPIs between Hsp70 and 
its many co-chaperones may be an effective approach. In the following sections, each co-
chaperone is discussed in more detail and some of the successes and challenges associated 
with each are outlined. 
 
1.5 J protein co-chaperones 
J proteins are a class of Hsp70 co-chaperones whose diversity in structure and function are 
thought to be crucial to the flexibility of the Hsp70 machinery. Evolution has dramatically 
expanded the cellular complement of J proteins relative to Hsp70s, such that humans have 
over 40 J protein-encoding genes but only 13 Hsp70 genes [50, 51]. Moreover, the co-
existence of many J proteins within the cytosol and nucleus suggests that they have evolved 
for distinct functions [52, 53]. All J proteins share a conserved J domain that binds to Hsp70 
but they diverge in other regions, perhaps providing the functional diversity needed to 
recruit Hsp70 into many different cellular activities. Consistent with this idea, various J 
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proteins have been linked to an array of pathological conditions including cancer, 
neurodegeneration, muscular dystrophy, and viral infection [54-58]. Thus, J proteins may be 
interesting targets for pharmacological targeting because they might be used to impact only 
a relatively narrow subset of Hsp70-dependent functions. 
 
1.5.1 J protein structure and function 
The J domain is a highly conserved structure that consists of four α-helices. The J domain 
interacts directly with the NBD of Hsp70 to stimulate ATP hydrolysis and allosteric 
conversion into a high-affinity substrate binding conformation [59-61]. For the bacterial 
DnaJ-DnaK interaction, the interface consists of the positively charged helix II of the J 
domain interacting electrostatically with the negatively charged NBD in lobes IA and IIA 
[36, 62-64]. J domains include an invariant His-Pro-Asp (HPD) motif in the loop between 
helices II and III that is required for function, perhaps by controlling the position of the 
helices. Though the overall four-helix architecture of the J domain is largely conserved 
among J proteins, subtle structural differences suggest that some functional diversity may 
arise from J domain interactions with Hsp70 [65]. For example, mutants in the NBD of the 
yeast BiP disrupt interactions with only a subset of available J proteins [66, 67]. Although 
speculative, these findings suggest that it might be possible to independently target specific J 
domains at the contact surface with Hsp70. 
 
J proteins have been traditionally grouped into three classes based on structural homology 
to the Escherichia coli DnaJ (Figure 1.3A). Class A consists of an N-terminal J domain, a 






 C-terminal domain (CTD), and a dimerization domain [68, 69]. Class B has the N-terminal 
J domain and G/F region, lacks a ZFLR, and is more structurally variable at the C-
terminus, but often contains two CTDs (CTDI and CTDII) [51]. Class C, the largest class, 
consists of proteins containing a J domain and with no other structural homology to DnaJ. 
More recently, Kampinga and Craig have provided a revised classification system based 
more closely on function [69]. This classification represents an important new paradigm in 
thinking about J proteins and it highlights the major contribution of J proteins to directing 
the activity of Hsp70. 
 
1.5.2 Diversity of J protein functions 
Specific functions have been described for only some of the individual J proteins and much 
more work is needed to clarify this area (see Chapter 2). However, some convincing and 
illustrative examples have been elucidated. One such is auxilin (DNAJC6), which has a C-
terminal J domain and a clathrin-binding domain. This J protein is exclusively involved in 
the Hsc70-dependent uncoating of clathrin-coated vesicles [70-72], an activity not readily 
redundant with other J proteins. Similarly, DNAJC7 interacts with both Hsp70 and Hsp90 
and seems to play a “recycling” role in the chaperoning of specific substrates, such as the 
progesterone receptor [73]. In the ER, ERdj3 (DNAJB11) works with BiP to assist with ER-
associated degradation (ERAD) [74, 75]. These and other examples [76] lead to a 
speculative model in which individual J proteins might be responsible for each of Hsp70’s 
specific functions. In support of this idea, a systematic study of human J proteins found that 
some examples are able to refold luciferase, while others inhibit aggregation of heat-
denatured luciferase [53], suggesting that these co-chaperones may be specialized. 
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1.5.3 J proteins bind substrates directly 
One prevailing model is that J proteins bind to substrates and present them to Hsp70. While 
this concept is likely oversimplified when applied to the large family of J proteins, the 
interaction of these co-chaperones with substrates seems to play a crucial role in some cases. 
For example, Lu and coworkers deleted the J domain of Ydj1 (yeast DNAJA1) and found 
that the remaining portion suppresses rhodanese aggregation on its own [77]. Later work 
identified a shallow hydrophobic depression on the CTDI of Sis1 (yeast DNAJB1) and 
found that four point mutants inhibited luciferase binding and refolding [78]. These types of 
studies suggest that J proteins can bind directly to substrates. Further insight into how J 
proteins bind to their substrates has largely been gained from peptide microarray studies. 
These studies have revealed that the prokaryotic DnaJ binds ~8mer peptides enriched in 
hydrophobic residues [79]. Interestingly, DnaJ does not discriminate between all-L-peptides 
and all-D-peptides with differing backbone stereochemistries, indicating that peptide binding 
involves side chain interactions [79, 80]. However, a crystal structure of the Ydj1 C-
terminus, which is highly homologous to DnaJ, bound to the peptide GWLYEIS, suggests 
that the peptide forms a β-strand alongside a β-sheet in CTDI and several contacts are made 
with the peptide backbone [81] (Figure 1.3B). This discrepancy may be due to species 
differences and the general rules for J protein-substrate interactions are not yet clear. 
However it is reasonable to hypothesize that formation of Hsp70-J protein-substrate ternary 




1.5.4 J proteins bind the C-terminus of Hsp70 
The four C-terminal residues of Hsp70, EEVD, seem to be important in regulating Hsp70 
activity and its interactions with J proteins. For example, deletion or mutation of this motif 
in Hsp70 prevents formation of stable Hsp70-substrate complexes and the stimulation of 
Hsp70 ATPase activity by DNAJB1 [82]. The EEVD motif is also crucial for Hsp70 
interactions with TPR-domain containing co-chaperones (see section 1.10). Further studies 
with Sis1 (yeast DNAJB1) found that this J protein could bind the eight C-terminal residues 
of Ssa1 (yeast Hsc70) with low micromolar affinity [83, 84]. Interestingly, Ydj1 (yeast 
DNAJA1) could not bind the Hsp70 C-terminus, suggesting distinct mechanisms for Hsp70 
regulation between the A and B classes of J proteins. A crystal structure of Sis1 (yeast 
DNAJB1) with the C-terminal lid of Ssa1 (yeast Hsc70) found that only the 7 terminal 
residues of Ssa1 were ordered and bound to Sis1 in the same binding groove used by  
substrate peptides in Ydj1 [84] (Figure 1.3B). However, the nature of this binding 
interaction is quite different. Ydj1-GWLYEIS is a mostly hydrophobic interaction, while 
Sis1-PTVEEVD is mediated by charge-charge interactions between four lysines in Sis1 and 
the EEVD motif [81, 84]. These lysines are conserved in class B J proteins but not class A, 
perhaps explaining Ydj1’s failure to interact with the C-terminus of Ssa1 [84]. Interestingly, 
a crystal structure of DNAJB1 with the C-terminal octapeptide of human Hsp70 
(GPTIEEVD) revealed two peptides bound to a single monomer of DNAJB1, one in the 
previously identified site and another in a site on the reverse side of the CTDI domain [85] 
(Figure 1.3B). Based on their findings and a re-examination of previous data, the authors 
propose that the originally identified site in class B J proteins is specific for Hsp70 binding, 
and the second site (which is shallow and hydrophobic) is dedicated to substrate binding. 
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With this in mind, they propose a model of J protein-Hsp70 activity in which one half of a J 
protein dimer binds Hsp70 and the other binds substrate, thus bringing the two together. 
This model might explain why Sis1 regulation of Hsp70 activity (e.g. luciferase refolding) 
requires a dimer and the Sis1 monomer is nonfunctional [82, 86]. These findings provide 
further evidence that ternary complexes of Hsp70 and J proteins with substrate are 
important for functional outcomes and perhaps substrate selection. 
 
1.6 Roles of J proteins in disease 
J proteins have been specifically implicated in the quality control of several pathologically 
relevant proteins, primarily in diseases of protein misfolding [87]. For example, DNAJB1 
and DNAJB6 can inhibit the aggregation and toxicity of mHtt, the misfolded protein in 
Huntington’s disease [88-90], while DNAJB1 and DNAJA1 co-localize with mHtt 
aggregates [91]. Interestingly, DNAJA1 over-expression increases mHtt aggregation [92], 
suggesting that each J protein might play a specific and sometimes opposing role in directing 
the fate of Hsp70 substrates. This concept is further illustrated by studies on the Hsp70 
substrate, tau [93]. In this system, DNAJB1 inhibits aggregation of tau in vitro [94], while 
DNAJA1 over-expression causes proteasome-dependent degradation of tau [95]. As Hsp70 
has been shown to have a direct role in the chaperoning of pathological substrates, some of 
these J protein phenotypes likely involve communication between Hsp70 and the J proteins, 
while other outcomes may be Hsp70 independent. Further work is needed to establish direct 
links between specific J protein-substrate interactions and phenotypic outcomes, particularly 
pathologically relevant ones. When these interactions are better understood, these co-
chaperones may constitute viable pharmacological targets.  
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1.7 Efforts to target J proteins 
While individual J proteins have not been pharmacologically targeted, several compounds 
have been developed that target the J domain-Hsp70 interaction. The first modulator of 
Hsp70 ATPase activity identified was 15-deoxyspergualin (DSG), a modified natural 
product that stimulates cytosolic Hsp70 ATP hydrolysis but does not inhibit or act 
synergistically with J protein stimulation [96-98]. Screens for structurally similar molecules 
identified R/1, a long, hydrophobic molecule that inhibits both intrinsic and J protein-
stimulated ATPase activity of the yeast cytosolic Hsp70, Ssa1, and the human ER Hsp70, 
BiP [99] (Figure 1.4). Another class of Hsp70 modulators that acts at the J protein level is 
the sulfogalactosyl ceramide (SGC) mimics. SGC is a cell surface receptor that binds the 
NBD of multiple members of the Hsp70 family [100, 101]. Park and coworkers developed a 
soluble mimic of SGC called adamantylSGC (AdaSGC), which inhibits the J protein-
stimulated ATPase activity of Hsc70 but not its slow intrinsic ATPase activity, suggesting 
that AdaSGC may directly inhibit the J domain-Hsp70 interaction [102].  
 
1.7.1 High throughput screens provide further Hsp70-J protein modulators 
More recent high throughput screening (HTS) efforts have identified additional compounds 
that specifically influence J protein-stimulated Hsp70 ATPase activity. For example, 
screening of a collection of dihydropyrimidines identified three examples, including MAL3-
101, that had no effect on intrinsic Hsp70 ATP turnover but inhibited J protein-stimulated 
turnover [103]. Subsequent screening and structural studies showed that the 
dihydropyrimidines bind to a region at the J protein-Hsp70 interface [104-106]. Moreover, 
these studies also found that some dihydropyrimidines promote J protein activity, while 
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others are inhibitory. For example, 115-7c is able to stimulate the ATPase activity of Hsp70 
synergistically with DnaJ [104]. 115-7c binds better to the DnaJ-DnaK complex than DnaK 
alone and nuclear magnetic resonance (NMR) studies found that 115-7c binds directly 
adjacent to the J domain-binding site on DnaK. However, the related compound 116-9e, 
which (similar to MAL3-101) has a diphenyl substitution on the dihydropyrimidine ring, 
inhibits DnaJ stimulation of ATPase activity, without impacting NEF function [104]. 
Interestingly, MAL3-101 seems to discriminate between J proteins, because it inhibits Ssa1 
stimulation by SV40 large T Antigen (TAg), a viral J protein, but had less potent activity 
against the combination of Ssa1 and Ydj1. This finding suggests that it may be possible to 
achieve J protein-specific inhibition even by targeting the J protein-Hsp70 interface. MAL3-
101 was subsequently found to have potent anti-cancer effects in a multiple myeloma cell 
line and mouse model [107], while other dihydropyrimidines have been found to control 
stability of other Hsp70 substrates, including tau, polyglutamines and Akt [48, 73, 108, 109].  
This growing body of work suggests that targeting the Hsp70-J protein interface may be a 
productive approach for guiding Hsp70 functions. Importantly, these compounds are not 
generally cytotoxic and they do not activate a stress response [48, 108, 109], consistent with 




Other chemical series also appear to have activity against the Hsp70-J protein interaction 
and, interestingly, some of these compounds use mechanisms different than the one used by 
the dihydropyrimidines. For example, an HTS effort against the DnaK-DnaJ pair identified 
the flavinoid myricetin, which inhibits DnaJ-stimulated ATPase and substrate binding  
activities, without affecting intrinsic or GrpE-stimulated activity [48, 110]. NMR revealed 
that myricetin binds the NBD in a region between the IB and IA subdomains, which is more 
than 20 Å away from the J domain-binding site [110]. However, despite this distance, 
myricetin blocks binding of DnaJ to DnaK, suggesting that it acts through an allosteric 
 
 19 
pathway. Additional HTS efforts have shown that methylene blue (MB) block J stimulation 
of ATP turnover in vitro. However, like myricetin, MB’s effects in cells and animals are 
complex and it is likely to have targets other than Hsp70s [48, 73, 111]. Despite this 
complexity, MB and myricetin have clearly shown Hsp70-dependent effects on pathological 
substrates in cellular and animal models [48, 73, 112] and they reduce Akt levels in cancer 
cells [109]. Interestingly, these effects are blocked by co-administration of 115-7c, the 
dihydropyrimidine activator of J protein function [48], further suggesting that the Hsp70-J 
protein contact is critical. Finally, a larger HTS effort using more than 55,000 compounds 
identified that zarkulifast is also an inhibitor of the DnaK-DnaJ combination [113] and a 
screen of more than 300,000 compounds identified an inhibitor of TAg [114]. The binding 
site of these molecules is not yet known, but the results show that screening strategies can be 
used to identify specific inhibitors of a PPI in the Hsp70 system. Like the 
dihydropyrimidines, some of these are likely orthostatic, while others may be allosteric, like 
myricetin. 
 
The effects of small molecules on disease-relevant Hsp70 substrates are an initial indication 
that this is a promising avenue of investigation. However, J protein biology is complex and 
more work is needed to rationally refine these studies to focus on specific J protein-Hsp70 
pairs. More specifically, if a discrete Hsp70-J protein pair can be clearly attributed to a 
distinct pathobiology, then HTS approaches might be employed to selectively disrupt (or 




1.8 Nucleotide exchange factors 
Nucleotide exchange factors (NEF) provide another potential “handle” for targeting the 
Hsp70 chaperone complex. NEFs bind Hsp70 and help to facilitate the exchange of ADP 
for ATP. The biochemisty of the NEF family of co-chaperones has classically been 
investigated using the prokaryotic NEF, GrpE, as a model [115]. However, the eukaryotic 
cytosol does not contain a GrpE homolog. Rather, there are three main sub-classes of 
human NEFs: Hsp110, HspBP1, and the BAG proteins, all of which are structurally distinct 
with little to no sequence homology. Consistent with their diverse structures, they also differ 
in their mode of binding to Hsp70s and their roles in guiding Hsp70 biology. For example, 
BAG2 is associated with proteasomal degradation of the Hsp70 substrate, tau, while BAG1-
Hsp70 is linked to increased tau stability [116, 117]. These observations suggest that the 
formation of specific NEF-Hsp70 complexes may help decide the fate of Hsp70-bound 
substrates. Also, these observations suggest that differential disruption of specific Hsp70-
NEF contacts might be beneficial in disease. For example, members of the NEF family are 
differentially expressed in multiple diseases, including cancer, Alzheimer’s, 
cardiomyopathies, and ischemia [118-121], highlighting the rationale for developing 
chemical modulators of NEF-Hsp70 interactions. 
 
1.8.1 Human NEF class: Hsp110 
Hsp110 was originally observed and classified as a heat shock protein based on the 
appearance of a 110 kDa band in the lysates of Chinese Hamster Ovary (CHO) cells upon 
heat shock [122]. In humans the major cytosolic Hsp110 protein is called Hsp105 (HSPH1) 
and it has two major isoforms α and β [123]. Hsp105α is constitutively expressed and 
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upregulated by a variety of stressors, whereas the alternatively spliced isoform Hsp105β is 
only induced upon heat shock [123, 124]. Hsp110 is an evolutionary relative of the Hsp70 
family and therefore it has very similar domain architecture, with the main differences 
including a longer acidic loop region between the β-sandwich and α-helical lid of the SBD 
and a larger unstructured C-terminal extension [125, 126].  Despite the structural similarity, 
Hsp110 only functions as a holdase (i.e. it maintains substrates in a stable, unaggregated 
form) and has no ability to refold substrates without the help of the Hsp70 machinery [126-
130]. Furthermore, while Hsp110 homologs bind nucleotide, this function seems to be 
dispensable for their NEF activity [131]. The crystal structure of the complex between 
Hsp70 and yeast Hsp110, Sse1, shows that the interaction covers a large surface area 
involving their respective NBDs [132, 133]. This interaction between Hsp70 and Hsp110 
causes several rotations in Hsp70’s NBD, especially in lobe IIB [134], allowing ADP 
release.  
 
1.8.2 Challenges of targeting Hsp110-Hsp70 interactions 
The large buried surface area between Hsp70 and Hsp110 may make targeting this 
interaction difficult. The problem in PPI systems like this is that binding energy is often 
distributed across a large and complex topology, precluding easy inhibition by small (<500 
Da) molecules. However, inhibiting PPIs with large surface areas is not unprecedented and 
compounds with potency values in the low nM range have been reported [135]. A common 
feature of previous successful strategies is that the small molecules tend to target so-called 
“hotspots” of the PPI, meaning that the inhibitor binds in a region on one partner 
containing a small number of residues that are responsible for the majority of the binding 
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strength [136, 137]. Thus, it will be important to identify residues that are critical to the 
Hsp70-Hsp110 interaction. Another common feature of successful PPI inhibitors is that they 
bind in allosteric sites to impact the topology of protein-protein contact surfaces from a 
distance. This approach lets the small molecule bind in a relatively concise pocket and 
impact larger surfaces to block PPIs. It seems likely that similar mechanisms will need to be 
employed to target the Hsp110-Hsp70 interaction. 
 
1.8.3 Human NEF class: BAG proteins 
Possible strategies to target the Hsp70-NEF interaction are illustrated by the features of the 
BAG family of co-chaperones, which includes BAG1-6. BAG proteins are defined by a 
characteristic C-terminal BAG domain that binds lobe IB and IIB of Hsp70’s NBD and 
facilitates nucleotide release [138, 139]. This BAG domain typically consists of 110 to 124 
amino acids and forms a three-helix bundle with the second and third helices providing the 
binding interface for Hsp70 [37, 140]. The association between the BAG domain and Hsp70 
causes a 14° rotation in lobe II, which results in an opening of the nucleotide binding cleft 
and promotes ADP release [37]. Interestingly, while all BAG proteins interact with Hsp70 
through their conserved BAG domains, their N-terminal region is highly variable. This 
diversity is likely to be key for pathway specificity and BAG proteins may use these 
domains to determine the timing and location of nucleotide-dependent delivery of Hsp70-
bound cargo.  
 
One of the major questions in this field is whether the structural differences between the 
major NEF classes can be exploited to produce selective inhibitors of the various families. 
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Similarly, can different members of the BAG family be individually targeted? Further, it 
isn’t yet clear how many NEF functions are dependent on Hsp70 and how many are 
independent.  
 
1.9 Tetratricopeptide-repeat (TPR) domain-containing proteins 
Hsp70s also cooperate with a number of TPR domain-containing proteins. The TPR motif 
is defined by a degenerate 34 amino acid sequence that forms an amphipathic antiparallel α-
helix [40, 141-144] and a TPR domain is typically assembled from 3 to 16 tandem TPR 
motifs. Although first identified in subunits of the anaphase promoting complex [145, 146], 
the TPR domain has since been found to be a common feature of protein-protein 
interactions, including those with Hsp70 co-chaperones.  
 
TPR co-chaperones include a wide range of proteins that include TPR domains for binding 
to Hsp70 or Hsp90 and additional domains involved in other functions [40, 141-144]. For 
example, the TPR co-chaperone Hop (Hsp70/Hsp90 organizing protein) has three TPR 
domains: TPR1, TPR2A, and TPR2B. Of these domains, TPR1 and TPR2A mediate the 
association with Hsp70 and Hsp90, respectively [147, 148]. Thus, Hop facilitates the 
coordination of Hsp70 and Hsp90, ultimately allowing for the transfer of substrate between 
these two chaperone systems [149, 150]. This coordination allows Hop to play a central role 
in the folding of non-native protein substrates, such as nuclear hormone receptors [151, 
152]. In contrast, the TPR co-chaperone CHIP (carboxyl terminus of Hsc70 interacting 
protein) is a ubiquitin E3 ligase with an effector Ubox domain [153]. This co-chaperone 
directs ubiquitination of Hsp70-bound substrates, marking them for proteasome-mediated 
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degradation [154, 155]. Thus, when Hop and CHIP compete for binding to Hsp70 through 
their TPR domains, they establish a choice between two opposing fates: folding vs. 
degradation. These findings clarify our understanding of the combinatorial assembly of 
Hsp70 complexes, in which mutually exclusive binding of Hsp70 to specific co-chaperones 
dictates the fate of substrates [156-158]. Taken together, these features suggest that 
chaperone complexes may have the potential to be chemically modulated in order to “tune” 
the proteome. 
  
1.9.1 TPR-domain containing protein interactions with Hsp70 
TPR co-chaperones interact with the intrinsically disordered C-terminus of Hsp70. 
Mutagenesis studies [148, 159, 160] and co-crystal structures of the TPR domains of Hop 
and CHIP with Hsp70 C-terminal peptides [147, 161] illustrate the importance of the C-
terminal EEVD-COOH amino acids [159, 162]. Based on these findings, the EEVD motif of 
Hsp70 has been generalized as the minimal binding site for TPR co-chaperones. This motif 
is also present in extreme C-terminus of the evolutionarily unrelated molecular chaperone 
Hsp90, but not in the prokaryotic DnaK, mitochondrial, or ER-resident Hsp70 isoforms. 
These observations highlight the role of the EEVD motif as a recruitment element that 
anchors TPR co-chaperones to the cytoplasmic Hsp70 and Hsp90 chaperone systems. 
However, there is not much known about how TPR co-chaperones “compete” for binding 
to Hsp70s. Thus, compounds that block the EEVD-TPR interaction might be exciting 





1.9.2 Targeting TPR-Hsp70 interactions 
The development of small molecule modulators of Hsp70-TPR complexes is still in its 
infancy. However, in the Hsp90 system, Yi and co-workers have targeted the TPR-domain 
of Hop and identified pyrimidotriazinediones as inhibitors of that protein-protein interaction 
[163]. Additionally, derivatives of the natural product sansalvamide A have been shown to 
modulate Hsp90 interactions with TPR co-chaperones [164, 165]. Taken together, this work 
suggests that the Hsp70-TPR interactions may also be amenable to inhibition. Compared to 
the other PPIs (e.g. J proteins and NEFs), the interactions between TPR domains and 
Hsp70s are relatively more concise, which might accelerate discovery in that area. The 
challenges will be in understanding how to engender selectivity and guide the “choice” of 
TPR partner. 
 
1.10 Future perspectives 
Targeting the Hsp70 chaperone machinery is a complicated endeavor. The sheer number of 
interactions involved – Hsp70-substrate, Hsp70-co-chaperone, co-chaperone-substrate, etc. – 
is daunting. Furthermore, the nature of the interactions (often low affinity, transient, high 
surface area, or all of the above) poses a challenge that will require significant effort to 
overcome. Before attempting to disrupt any individual interaction for therapeutic purposes, 
it is important to understand the nature of individual interactions and their roles in both 
health and disease. A particular challenge of this system is that Hsp70 and its partners play a 
plethora of roles in normal biology, so any chemical intervention has a high probability of 
off-target effects. In lieu of targeting Hsp70 itself, co-chaperones provide a tantalizing route 
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to specificity of chaperone-targeted therapies. Further work is necessary to identify specific 
activities of individual co-chaperones in order to guide therapy design.  
 
This thesis presents multiple approaches to studying chaperones as networks of cooperating 
and competing elements. In Chapter 2, the functional roles of 11 J proteins in Saccharomyces 
cerevisiae are probed using a chemical genetics approach. In Chapter 3, a peptide microarray 
platform is used to identify the binding sites of many chaperones and co-chaperones on a 
pathological substrate, tau, which is implicated in Alzheimer’s disease and other 
neurodegenerative diseases. In Chapter 4, peptide microarrays are again leveraged to 
evaluate the binding of chaperones to peptides that are known or predicted to form the cores 
of amyloid fibrils. Finally, in Chapter 5, the questions raised by this work are discussed and 
future goals outlined. 
 
Notes 
This work was published in part as a review titled “Hsp70 Protein Complexes as Drug 
Targets” 2013 Current Pharmaceutical Designs, 19(3), 404-17.  Anne Gillies, Victoria Assimon, 
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J proteins are a diverse family of co-chaperones that cooperate with heat shock protein 70 
(Hsp70) to coordinate protein quality control, especially in response to cellular stress. 
Current models suggest that individual J proteins might play roles in recruiting Hsp70s to 
specific functions, such as maintaining cell wall integrity or promoting ribosome biogenesis. 
However, relatively few stresses have been used to test this model and, as a result, only a 
few specific activities have been identified. To expand our understanding of the J protein 
network, we used a synthetic lethal approach in which 11 Saccharomyces cerevisiae deletion 
strains were treated with 12 well-characterized chemical inhibitors. The results defined new 
roles for specific J proteins in major signaling pathways. For example, an important role for 
Swa2 in cell wall integrity was identified and activities of the under-explored Jjj1, Apj1, Jjj3 
and Caj1 proteins were suggested. More generally, these findings support a model in which 
some J proteins, such as Ydj1 and Zuo1, play “generalist” roles, while others, such as Apj1 
and Jjj2, are “specialists”, having roles in relatively few pathways. Together, these results 





2.2.1 Hsp70 and J proteins in S. cerevisiae 
In Saccharomyces cerevisiae, there are two cytosolic classes of Hsp70: Ssa (Ssa1-4) and Ssb 
(Ssb1-2). Expression of only one of each class is required to support near wild type viability, 
underscoring the high structural and functional homology among Hsp70 isoforms [1]. 
 
The dramatic expansion of the J proteins in higher organisms, especially compared to the 
relatively few Hsp70s, suggests that a larger pool of more specialized J proteins supports 
greater cellular complexity. Prevailing models suggest that combinations of an individual J 
protein with an Hsp70 might yield a complex with the ability to perform specific tasks or 
engage with specific subsets of substrates. In support of this idea, recent efforts have 
identified roles for individual J proteins in a handful of specific cellular tasks. For example, 
Swa2, the S. ceresvisiae ortholog of human auxilin, uncoats clathrin coated vesicles and is 
required for cortical ER inheritance [2, 3]. This activity is not readily recovered by over-
expression of other J proteins, suggesting that Swa2 is specialized for this Hsp70 function. 
Similarly, Jjj3 is a J protein that is essential for diphthamide synthesis [4]. In contrast to 
these “specialist” J proteins, S. cerevisiae has also retained “generalists”, such as Ydj1 and 
Sis1, which maintain protein quality control in the cytosol by helping Hsp70 fold proteins 
[5]. A systematic study of cytosolic S. cerevisiae J proteins using deletion mutants confirmed 
that some J proteins play essential roles during thermal stress, while others are apparently 
redundant for this activity [1]. These observations suggest that other J proteins might be 




2.2.2 Elucidation of J protein functional roles in S. cerevisiae 
We envisioned that a synthetic lethal approach might enable assignment of cellular roles to 
individual J proteins. Using deletions of the 11 cytosolic J proteins in S. cerevisiae [1, 6, 7], 
we tested the effects of twelve well-characterized chemical inhibitors that act in specific 
cellular pathways, such as cell wall synthesis and translation (Table 2.1), on growth [6, 8]. 
We found that some J proteins, such as Ydj1, are multidrug resistance genes, required to 
buffer the cell against a diverse array of stressors. Others confer resistance to only a subset of 
the compounds, suggesting functions in specific pathways. Three J proteins had no synthetic 
lethal interactions and they may either be redundant or have specific functions in pathways 
not targeted by the twelve compounds. These findings define new biological roles for 
individual J proteins, results that could facilitate their functional classification and provide 




Hygromycin B Translation; 30S ribosomal subunit formation 
Cycloheximide Translation elongation 
Rapamycin TOR1/TOR2 signaling 
Caffeine TOR1 signaling; cell wall; other kinases 
Calcofluor White Cell wall integrity (CWI) pathway 
Congo Red Cell wall integrity (CWI) pathway 
Fluconazole Ergosterol biosynthesis (plasma membrane) 
17-AAG Hsp90 
Camptothecin Topoisomerase I 
Hydroxyurea Ribonucleotide reductase 
FK-506 Calcineurin 
Wortmannin Phosphatidylinositol kinase 
Table 2.2. Compounds with known antifungal activity tested for 
synthetic lethal interactions with J proteins in S. cerevisiae. 
2.3 Results 
2.3.1 Selection of J proteins and chemical probes for synthetic lethal analysis 
Eleven S. cerevisiae deletion mutants of cytosolic and nuclear J proteins were selected to 
carry out chemical genetic investigations [1] (Table 2.1). These J proteins represent 3 
members of class I, 2 of class II and 6 of class III. In addition, twelve compounds targeting 
diverse cellular processes were chosen [6, 7] (Table 2.2). Yeast strains were spotted in five-
fold dilutions on rich media agar containing a sublethal concentration of each compound 
and grown for three days. As a secondary assay, yeast growth in liquid was also assessed 
using optical density (OD) values monitored for 10 hours, when all strains had reached 
stationary phase. Compounds that reduced growth of a J protein deletion strain in either 
assay were scored as synthetic lethal interactions. 
2.3.2 Ydj1 
Ydj1 is an abundant J protein that partners with Hsp70s (Ssa1-4 in yeast) to carry out 




of Ydj1 resulted in sensitivity to nearly every compound tested (Figure 2.1A). Δydj1 cells 
were particularly sensitive to translation inhibitors, fluconazole, rapamycin and caffeine 
(Figure 2.1A). Furthermore, Δydj1 was very sensitive to wortmannin, an inhibitor of PI 
kinases, in the liquid growth assay (Figure 2.1B). Together, these results suggest that Ydj1 
may play an important role in supporting the integrity of kinase signaling networks, perhaps 
by stabilizing the enzymes. On the other hand, Δydj1 was only moderately sensitive to cell 
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wall stressors, suggesting that cells lacking Ydj1 can still maintain the cell wall integrity 
(CWI) pathway. Finally, Δydj1 was the only strain tested that was mildly sensitive to the 
stressors of DNA maintenance, hydroxyurea and camptothecin. This result suggests that the 
J proteins (and, by extension, the Hsp70 machinery) may not be responsible for stability or 
function in that system. 
 
2.3.3 Zuo1 
Zuo1 is a ribosome-associated J protein that plays roles in nascent protein folding and 
ribosomal assembly [11-13]. Deletion of Zuo1 resulted in marked sensitivity to seven 
compounds (Figure 2.1A). The sensitivity profile of Δzuo1 was similar to that of Ydj1, which 
is unexpected because they have markedly different localization patterns and domain 
structures (Table 2.1). For example, Δzuo1 was acutely sensitive to fluconazole, rapamycin, 
caffeine, and wortmannin (Figure 2.1A,B) and these cells also had moderate sensitivity to 
cell wall perturbing compounds. It seems possible that the similar sensitivities of Δzuo1 and 
∆ydj1 cells may reflect their activities at different stages in the same processes. For example, 
Zuo1 might be important in initial folding of a kinase, while Ydj1 might be important in 
final maturation. However, Δzuo1 cells do not share the growth defect of Δydj1 cells, so it 
may be that Ydj1’s role is more critical to a wider range of substrates. Consistent with this 
idea, Δzuo1 was not sensitive to inhibitors of Hsp90, DNA-modifying enzymes or 
calcineurin. Another possibility is based on the observations that Zuo1 promotes expression 
of the drug exporter Pdr5 [14, 15]. The absence of Zuo1 may therefore allow accumulation 
of the specific drugs exported by Pdr5, which includes fluconazole (Figure 2.1A). Finally, as 
expected, Δzuo1 cells were not viable in the presence of compounds that inhibit translation 
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(Figure 2.1A,C). In healthy cells, Zuo1 may confer tolerance to cycloheximide and 
hygromycin B by helping to disassemble arrested ribosomes and assemble new ones, and in 
its absence the cells cannot recover from the accumulation of arrested ribosomes. 
 
2.3.4 Swa2 
Swa2 functions with Hsp70s in the removal of clathrin from vesicles [2] and it has essential 
roles in cortical ER inheritance [3]. In addition to its J domain and clathrin-binding domain, 
Swa2 includes three tetratricopeptide (TPR) motifs and a ubiquitin-binding domain [16]. 
Deletion of Swa2 caused sensitivity to 6 compounds (Figure 2.1A), including weak 
sensitivity to caffeine and rapamycin and severe responses to calcofluor white, congo red, 
fluconazole, and hygromycin B. Lesser sensitivity was also observed in the presence of 
cycloheximide, caffeine, and rapamycin. The acute sensitivity of Δswa2 to cell wall 
perturbing agents suggests that Swa2 may have a role, whether direct or indirect, in cell wall 
assembly or integrity. CW and CR induce upregulation of the cell wall integrity (CWI) 
pathway, but caffeine causes cell wall defects independent of the CWI pathway [17, 18]. 
The severe sensitivity of Δswa2 to CW and CR but not caffeine thus suggests a specific 
defect in the cell’s ability to mount a CWI response in the absence of Swa2. This may be 
due to impaired trafficking of cell wall components or CWI pathway members as a result of 
accumulated clathrin coated transport vesicles, or it could be another uncharacterized 





Jjj1 is a specialized J protein that plays a role in 60S ribosomal subunit biogenesis [19, 20] 
and perhaps other aspects of ribosome turnover [13]. Deletion of this J protein conferred 
mild sensitivity to calcofluor white, rapamycin, cycloheximide, and fluconazole in the spot 
assay and hygromycin B and wortmannin in the liquid assay (Figure 2.2). Previous work 
has demonstrated that growth defects resulting from Jjj1 deletion cannot be ameliorated by 
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any other J protein [1]. On the other hand, overexpression of Jjj1 can partially rescue the 
slow growth of Δzuo1 cells, which is thought to be due to its ability to recruit Ssa1 (the 
cytosolic yeast Hsp70) to the ribosome when Zuo1 is not present to recruit Ssb1/2 [13]. 
Further enforcing this relationship between Jjj1 and Zuo1, their deletions confer sensitivity 
to nearly the same compounds in our experiments. However, loss of Jjj1 is less detrimental, 
as the phenotype of Δjjj1 cells is uniformly less dramatic. The differences in phenotype 
severity are consistent with their copy numbers; Jjj1 exists as only 2310 molecules per cell, 
while Zuo1 has 86400 copies and is possibly associated with every ribosome. Together, 




Jjj3 is one of the five genes required for synthesis of diphthamide (DT), a posttranslational 
modification of translation elongation factor 2 (EF2) [4]. Studies of the human ortholog of 
Jjj3, Dph4, found that it is an iron-binding enzyme that is capable of participating in redox 
processes, and it was confirmed that Jjj3 also possesses these properties [21]. In fact, one of 
the enzymes responsible for DT synthesis, Dph2, contains an iron-sulfur cluster, and it is 
likely that Dph4/Jjj3 cooperates with Dph2 [21]. In our synthetic lethal screen, deletion of 
Jjj3 conferred mild sensitivity to the TOR-targeting compounds, rapamycin and caffeine, 
and the translation inhibitor, cycloheximide (Figure 2A). Mild sensitivity of Δjjj3 to 
hygromycin B and wortmannin in the liquid assay was also observed (Figure 2.2B,C).  
These results clearly demonstrate that DT synthesis is not the only process in which Jjj3 is 
involved. Perhaps consistent with this model, Jjj3 is partially colocalized to the perinuclear 
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site of diphthamide synthesis, but there is a significant portion of the Jjj3 pool that associates 
with the broader cytoskeleton [22]. Interestingly, protein microarray studies suggest that Jjj3 
physically interacts with 8 kinases [23] and it was one of only 24/4200 proteins that 
interacted with 8 or more kinases, including kinases involved in the PKC pathway, septin 
behavior, cell cycle progression, and transcriptional activation [23]. Together, the previous 




Deletion of Apj1 conferred mild sensitivity to caffeine, rapamycin, cyclohexmide, calcofluor 
white, and wortmannin (Figure 2.2). The identification of phenotypes deriving from 
deletion of this J protein is remarkable given its extremely low abundance – there are merely 
125 copies of Apj1 in the cell [24]. This low number suggests that this J protein may need to 
be localized in order to carry out its functions. Indeed, Apj1 has been identified in stringent 
analyses of the mitochondrial proteome [25, 26]. Apj1 is a class I J protein and it is highly 
homologous to Ydj1 (35% identity).  It is therefore unsurprising that overexpression of Apj1 
can rescue loss of Ydj1 in functions such as prion propagation [27]. However, deletion of 
Apj1 confers two interesting phenotypes: suppressed RNA replication of flock house virus 
[28] and hypersensitivity to mutant huntingtin (mHtt) [29]. Though the phenotypes 
identified to date do not point to a clear single function of Apj1, it is evident that this J 
protein plays roles that cannot be fully compensated for by endogenous levels of other J 





Jjj2 is another low-abundance J protein (182 copies) [24], although no specific sub-cellular 
localization has been reported. It is a class III protein with no predicted domains other than 
the J domain. Deletion of Jjj2 conferred sensitivity to cycloheximide and fluconazole 
(Figure 2.2). These are the only two compounds tested that are exported by the PDR5 
transporter, suggesting that Jjj2 may support transporter expression or function, although 





Caj1 is thought to be located in the nucleus [30, 31] but is otherwise uncharacterized. In our 
synthetic lethal screen, ∆caj1 cells were largely indistinguishable from wild type, with only 
mild phenotypes in the presence of cycloheximide in the spot assay and hygromycin B in the 
liquid assay (Figure 3A, C). A previous large-scale chemical genetic screen also identified 
Δcaj1 as sensitive to cycloheximide [8], and together these findings suggest that Caj1 may be 
involved in transcription. 
 
2.3.10 J proteins with no observed synthetic lethal interactions 
These three J proteins exhibited no phenotypes in any of the conditions tested (Figure 3), 
suggesting that they either have roles in pathways not tested by these twelve compounds or 
that they are redundant under these conditions. It is known that Djp1 has a role in 
peroxisomal protein import, and it may be that this J protein is highly specialized for this 
role and no others [32]. Also, Xdj1 may not be expressed [33]. 
  
2.3.11 Hsp70s 
J proteins cooperate with Hsp70s to maintain protein quality control. When we treated 
∆ssa1, ∆ssa2, or ∆ssa4 cells with the twelve chemical inhibitors, no apparent growth defects 
were observed  (data not shown). These studies suggest that the Ssa proteins are redundant 
under these conditions. In light of this conclusion, the phenotypes resulting from deletion of 





These results provide additional details to the J protein network (Figure 4). Specifically, 
some J proteins, such as Ydj1 and Zuo1, have profiles that suggest broad roles in multiple 
cellular pathways, while others, such as Apj1 and Jjj2, seem to have focused cellular 
responsibilities. Although the current synthetic lethal analysis is certainly not inclusive of all 
possible stress conditions, these studies are supportive of a model in which J proteins have 
evolved to maintain a wide array of cellular processes, allowing Hsp70s to be recruited into 




What do these results reveal about J proteins in disease? One interesting possibility comes 
from comparing these findings to the results of experiments in which proteotoxic stress (e.g. 
over-expression of misfolded proteins) was used to evaluate J protein activity. Specifically, 
Jjj3 over-expression has been shown to suppress the toxicity of polyglutamine-expanded 
huntingtin (Htt) [34]. This finding has direct relevance to our results because TOR inhibition 
activates autophagy and clearance of mHtt [35, 36] and we found that ∆jjj3 cells are 
sensitive to rapamycin. Similarly, we found that Apj1 is sensitive to rapamycin and this J 
protein is also upregulated in cells expressing mHtt [34]. Thus, pharmacological targeting of 
individual J proteins or specific Hsp70-J protein combinations [37, 38] may be a compelling 
approach. 
 
2.5 Experimental Methods 
2.5.1 Materials 
Compounds were dissolved in dimethylsulfoxide (DMSO, Sigma Aldrich) or weighed out 
(caffeine and hydroxyurea) and added to yeast peptone-dextrose (YPD, Teknova) rich 
media plates to the following final concentrations: hygromycin B (InvivoGen, 50 µg/mL), 
cycloheximide (Sigma Aldrich, 0.25 µg/mL), rapamycin (LC Laboratories, 0.021 µg/mL), 
caffeine (Sigma Aldrich, 5 mM), calcofluor white (Sigma Aldrich. 20 µg/mL), congo red 
(Fluka, 20 µg/mL), fluconazole (Santa Cruz, 5 µg/mL), 17-AAG (LC Laboratories, 25 
µg/mL), camptothecin (Santa Cruz, 25 µg/mL), hydroxyurea (Santa Cruz, 100 mM), FK-




2.5.2 Yeast spot growth assay 
Yeast knockout strains were purchased from Open Biosystems (Thermo Scientific) in the 
BY4741 background (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0). Wild type and knockout strains 
were grown overnight in 5 mL YPD cultures. Cells were diluted to OD600 = 0.5 and 5-fold 
dilutions made in YPD. A micropipette was used to spot 3 µL of cells onto plates containing 
DMSO (1%) or compound.  Plates were inverted and incubated for 72 hours at 30oC, then 
imaged. 
 
2.5.3 Yeast liquid growth assay 
Compounds were dissolved in DMSO to 50 times the following final concentrations: 
wortmannin (24 µg/mL), hygromycin B (120 µg/mL), and calcofluor white (200 µg/mL). 
Two-fold serial dilutions were carried out in 96-well PCR plates (BioExpress), then 2 µL of 
each solution was transferred to a flat-bottom clear 96-well plate (CytoOne) using a 
multichannel micropipette. Yeast strains were grown overnight in 5 mL YPD cultures and 
diluted to OD600 = 0.15 in YPD, then 100 µL was added to each well of the plate. Plates 
were covered and incubated with shaking (200 RPM) at 30oC for 10 hours. OD600 values 
were measured using a microplate reader (Molecular Devices).  
 
Notes 
This work was published in full as a journal article: Gillies, A. T.; Taylor, R.; Gestwicki, J.E. 
“Synthetic lethal interactions in yeast reveal functional roles of J protein co-chaperones,” 2012 
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Peptide Microarrays Map the Binding Sites of Chaperones on Luciferase and Tau 
 
3.1 Abstract 
Molecular chaperones interact with unfolded proteins and promote a variety of outcomes, 
including folding, proteasomal degradation and autophagy. The mechanisms by which 
chaperones work together to carry out these functions are poorly understood. Current 
models suggest that the “choice” of chaperones and co-chaperones that bind the protein 
might dictate the outcomes, as discussed in Chapter 1. In this chapter, we used peptide 
microarrays to investigate the binding of purified chaperones to peptides derived from two 
substrates, firefly luciferase and microtubule associated protein tau (MAPT/tau). We found 
that the J proteins DNAJA2 and DNAJA1 have similar binding sites on luciferase, but that 
Hsc70 stimulated binding of DNAJA2 (not DNAJA1) to one of these sites. These results 
could help explain why DNAJA2 is capable of assisting Hsc70 in refolding luciferase, while 
DNAJA1 is not. To understand how a broader collection of chaperones might converge on 
a protein, we also mapped the binding of 17 chaperones to peptides derived from tau. We 
found that many chaperones, including Hsc70, Hsp72 and Hsp90, bind to “hotspots” on tau 
and that pro-stabilizing and pro-degradation chaperones share similar binding sites. These 
results provide new models for how competition between chaperones might play an 




Members of the Hsp70 and Hsp90 families of chaperones and some of their associated co-
chaperones bind directly to protein substrates (see Chapter 1). It is unknown how Hsp70s, 
Hsp90s and their co-chaperones come together on a single substrate – do they compete for 
the same binding sites? Do they bind simultaneously? How many binding sites for 
chaperones are present within a single, unfolded substrate? How do the locations and types 
of these physical interactions promote outcomes such as folding or targeting for 
degradation? In order to develop models for how these complexes form and how they 
cooperate during protein triage, we hypothesize that it will be necessary to understand the 
binding sites for chaperones on protein substrates. In this Chapter, we map the binding of 
chaperones and co-chaperones to peptides derived from two well-characterized substrates of 
the Hsp70 system: luciferase and tau.  
 
3.2.1 Luciferase is a model substrate for Hsp70 chaperone system 
Firefly luciferase has been used extensively to study chaperone function. Denatured 
luciferase is only weakly able to fold in the absence of chaperones and refolded luciferase 
can be conveniently measured by luminescence. Chaperone systems composed of a purified 
Hsp70, a J-protein and a nucleotide exchange factor (NEF), will refold denatured luciferase 
in the presence of ATP [1-3]. This model system has been used to explore the mechanisms 
of chaperone cooperation, especially the role of the J protein co-chaperones. For example, 
refolding is successful when denatured luciferase is incubated with the J protein and Hsc70 
added later, but not vice versa, suggesting that the J protein can bind and stabilize the 
unfolded substrate in the absence of Hsc70 [4]. J protein-luciferase interactions are in fact 
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necessary for productive luciferase refolding, as J domain-mediated stimulation of Hsp70 
ATPase activity is insufficient to catalyze folding [5]. However, not all J proteins are equally 
capable of supporting luciferase refolding. Ydj1 (yeast DNAJA1) is twice as competent in 
this system as Sis1 (yeast DNAJB1) [6, 7], which might be because Sis1 lacks the ZFLR 
domain (Figure 1.3B) [7]. In fact, point mutants in the two zinc-binding domains in the 
Ydj1 ZFLR nearly abolish luciferase refolding [8] and crosslinking experiments identified 
direct interactions between the ZFLR of DnaJ (E. coli DNAJA1) and luciferase [5]. These 
studies on luciferase suggest that J proteins interact directly with substrates using contacts in 
multiple domains, including the ZFLR and CTDI (Figure 1.3B). 
 
Additional studies using denatured luciferase have suggested that J protein domain structure 
is not the only determinant of luciferase refolding ability. For example, human DNAJA2, 
but not its close homolog, DNAJA1, can efficiently support luciferase refolding in vitro [9, 
10] and in cells [11]. The ZFLR domains of these J proteins are 57% identical and the CTDs 
are 55% identical, so modest sequence differences might be sufficient to specialize these co-
chaperones for interactions with different substrates. We explored this question using 
genetics in Chapter 2. However, a deeper understanding of the molecular details of 
chaperone binding to luciferase would provide important insights into the mechanism of 
chaperone-mediated refolding. 
 
3.2.2 Tau aggregation is a hallmark of Alzheimer’s disease  
Tau is a natively unfolded protein that forms aggregates characteristic of a class of 
neurodegenerative diseases called tauopathies, including Alzheimer’s disease (AD), 
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frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), and Pick’s disease 
(PD) [12-14]. Tau belongs to a class of microtubule-associated proteins (MAPs) and in 
healthy cells functions to facilitate microtubule assembly and regulate microtubule dynamics 
[15-17]. Though normal tau has only transient secondary structure and is highly soluble, it is 
able to undergo a structural conversion into rigid, ordered amyloid fibrils, termed paired 
helical filaments (PHFs) [18-22]. This conversion is thought to be one of the major 
pathological events of AD and other tauopathies, as the accumulation of intracellular tau 
deposits (neurofibrillary tangles, NFTs) correlates with cognitive decline and neuron loss 
[23-25]. The other major feature of AD, plagues composed of another protein called 
amyloid-β (Aβ), has long been thought to be the primary underlying cause of AD, partly 
due to the identification of disease-linked mutations in amyloid precursor protein (APP), 
which is cleaved to release Aβ [26, 27]. However, recent evidence has shown that tau plays 
an equally important role in AD pathology and that Aβ toxicity is actually dependent on tau 
[28-31]. Furthermore, identification of over 40 mutations in the tau gene in cases of FTD, 
collectively termed frontotemporal dementia and Parkinsonism linked to chromosome-17 
(FTDP-17), demonstrates that tau can be a direct cause of neurodegeneration [32-34]. 
  
Despite extensive research, the mechanism of tau toxicity is not well understood. Toxicity 
likely arises from a combination of loss of normal function and gain of pathological function 
upon formation of tau aggregates [35]. As pre-formed tau PHFs are not inherently 
neurotoxic, and may indeed constitute a mechanism by which the cell tries to protect itself, 
it appears that an intermediate stage of aggregation (e.g. tau oligomers) may constitute the 
toxic species [36]. In healthy neurons, tau is tightly regulated by a host of post-translational 
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modifications, including phosphorylation, nitration, ubiquitination, and others. 
Hyperphosphorylation is one of the most striking characteristics of tauopathies, suggesting 
that tau becomes dangerously disregulated [37, 38]. Approximately 45 phosphorylated 
residues have been identified in tau PHFs, including Ser, Thr, and Tyr residues. Many 
kinases are candidates for tau phosphorylation, including proline-directed (SP/TP) kinases 
such as glycogen synthase kinase-3 (GSK3), KXGS-motif recognizing kinases like 
microtubule affinity-regulating kinase (MARK), and non-receptor tyrosine kinases (Fyn, c-
Abl) [37]. Hyperphosphorylation reduces the affinity of tau for microtubules and increases 
its propensity to aggregate into PHFs [39]. Another outcome of the disregulation of tau is 
that it is mislocalized in tauopathies, moving from the axon into the somatodendritic 
compartment and perhaps leading to excitotoxicity through activation of Fyn, a non-
receptor tyrosine kinase linked to Aβ toxicity that can also phosphorylate tau [31, 40]. In 
tauopathies, tau also undergoes a host of truncations by caspases and other proteases that 
seem to enhance its toxicity [41, 42].  
 
In the adult brain, tau is expressed as six isoforms resulting from the alternative splicing of 
three exons. Two inserts of unknown function near the N-terminus give rise to three 
different variants (0N, 1N, 2N), and the presence or absence of the second of four imperfect 
repeats in the C-terminal repeat domain gives rise to two further variants (3R and 4R) 
(Figure 3.1). The repeat domain is also called the microtubule-binding region (MTBR) as it 
governs the interaction of tau with microtubules, though other parts of tau appear to be 
important for regulating this interaction as well. Another distinct region of tau is called the 
proline-rich domain, immediately upstream of the repeat domain. The most abundant 
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isoform of tau in the brain is 4R2N (also known as hTau40) and thus most biochemical 
studies have been carried out on this isoform, a 441 residue, 40 kDa protein. Despite the 
presence of these clear domains, the regulation and functions of tau cannot be easily pinned 
down to specific regions of the protein. For example, post-translational modifications and 
intermolecular interactions occur at residues throughout the entirety of the tau molecule, 
with different modifications and interactions often competing for similar sites [37, 43]. This 
complexity is the basis of our difficulty in understanding the fundamental biology of tau and 
its pathological mechanisms.   
 
3.2.3 Chaperones regulate normal tau and play a role in tauopathies 
Tau provides a medically important model substrate for understanding chaperone functions. 
Hsc70 and Hsp90, along with many of their co-chaperones, directly interact with tau and 
regulate its functions and homeostasis [44-46]. Hsp72 and Hsp90 work together with the E3 
ligase CHIP to target tau for proteasomal degradation (see Chapter 1), while other co-
chaperones favor re-binding of free tau to microtubules [47-49]. Over-expression of different 
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members of the J protein, NEF and FK506-binding protein (FKBP) classes of co-chaperones 
have distinct effects on tau stability [46, 50]. Further, the small heat shock protein, Hsp27, 
reduces tau pathology [51]. Together, these observations suggest that interplay between 
chaperones and co-chaperones regulates the normal and disease-associated functions of tau, 
including its turnover, aggregation and association with microtubules. In tauopathies, this 
quality control system appears to be dysfunctional or insufficient. An understanding of 
individual chaperone interactions with tau would provide critical insight into the regulation 
of this system and, perhaps, provide new opportunities for drug discovery 
 
The binding of chaperones to tau has been explored in a number of recent studies. Sarkar 
and coworkers used a truncation approach to identify two binding sites for Hsc70 and 
Hsp72 on tau: 275VQIINKK281 and 306VQIVYK311, located in R2 and R3 respectively [52]. 
These hexapeptides are very interesting because they comprise the backbone of the amyloid 
fibril structure at the core of PHFs (see Chapter 4) [53, 54]. This region is also involved in 
binding to microtubules [55], suggesting that binding of tau to either microtubules or Hsp70s 
might limit its aggregation into PHFs. However, mutations in the two chaperone-mediated 
autophagy (CMA) targeting motifs in R4 also abolish binding of tau by Hsc70, suggesting 
that tau-Hsc70 interactions are more complex [56]. Our group recently reported that Hsp72 
and Hsp90 compete for tau binding through shared binding sites, but that unique Hsp72 
binding sites allow it to outcompete Hsp90 in vitro, suggesting that varied expression levels 
of these chaperones may play a role in tau metabolism [48]. Further, we also recently 
showed that Hsc70 and Hsp72 have different effects on tau stability in cells, despite shared 
binding sites measured by NMR [57].  
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In this chapter, we explore the binding of chaperones to luciferase and tau using peptide 
microarrays. In these studies, we were interested in exploring how different classes of 
chaperones might cooperate or compete for binding to these proteins. By understanding 
how chaperones and co-chaperones converge on these proteins, we might provide insight 
into the logic and mechanisms of protein quality control.  
 
3.2.4 Studying protein-protein interactions with peptide microarrays 
Peptide microarrays were developed to study interactions of proteins with peptides in a high 
density format [58]. In this method, peptides are immobilized on a cellulose membrane or a 
glass slide and bound protein is detected using HRP-conjugated or fluorescent antibodies. In 
the glass slide format, binding is qualitatively determined by the amount of fluorescence at 
each peptide, similar to the commonly used DNA microarrays. Rüdiger and co-workers 
have used this method to study binding of DnaK (bacterial Hsc70) and DnaJ (bacterial 
DNAJA1) to luciferase and other substrates [59, 60]. Peptide arrays were also used to 
determined sites of DnaJ and DnaK interaction with the σ32 subunit of RNA polymerase 
[61] and the binding sites of human DNAJA1 and Hsc70 on luciferase [62].  
 
In this chapter, we used peptide microarrays to explore how chaperones interact with 
luciferase and tau. In the case of luciferase, we were particularly interested in why DNAJA1 
and DNAJA2 might differ in their ability to refold luciferase and we hypothesized that these 
co-chaperones might differ in their recruitment of Hsc70. We found that Hsc70, DNAJA1, 
and DNAJA2 have similar binding sites on luciferase, but that Hsc70 stimulates binding of 




We also explored binding of 17 different chaperones and co-chaperones to tau. These 
studies provided the first comprehensive map of chaperone binding to a protein substrate 
and yielded a complex map of interactions. Broadly, we found that chaperones tended to 
bind “hotspots” on the N-terminus, proline-rich and repeat domains of tau. We discuss the 
implications of these interactions on the function and homeostasis of tau and new models of 
chaperone cooperation are proposed.  
 
3.3 Results 
3.3.1 Luciferase peptide microarray design 
In order to identify the binding sites of Hsc70, DNAJA1, and DNAJA2 on luciferase, we 
designed a peptide microarray that scans the sequence of luciferase. The array consists of 15 
amino acid (AA) peptides with 4 AA steps along the sequence for a total of 135 peptides 
(Appendix 3.1). This degree of overlap was chosen to strike a balance between binding site 
coverage and the number of peptides to be synthesized. Each microarray printed on a glass 
microscrope slide consists of the peptide library printed in triplicate. 
 
The arrays were incubated with chaperones bearing a polyhistidine (His6x) tag. Bound 
chaperones were then detected with a fluorescently labeled anti-His6x antibody (see the 
Methods section for details). Fluorescence was detected using a GenePix 4100A microarray 
scanner and background-corrected intensity values were generated for each spot. The three  
signals for each peptide on the array were averaged and these values were used to identify 




3.3.2 Chaperones bind to several long continuous regions on luciferase 
On our luciferase arrays, all of the chaperones and chaperone mixtures tested exhibited 
qualitatively similar binding patterns. These consisted of long series of consecutive peptides 
with bright signal interspersed with stretches of little to no signal (Figure 3.2). The length of 
these stretches (4 to 12 peptides) and the 4 AA steps between peptides means that no amino 
acids are shared among all of the peptides in a stretch of binding. Therefore, they cannot 
point to a minimal binding site. However, the gradual increase and decrease of fluorescence 
intensity in these regions suggests that the central peptides may contain the most important 
residues. In general, our data suggests that Hsc70 and J proteins interact with larger regions 
of luciferase than the 7-13 AA peptide substrates usually discussed for these chaperones and, 
further, that these binding sites are not limited to hydrophobic AAs [63, 64]. This finding 
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could suggest either that multiple chaperones bind together on denatured luciferase or that a 
single chaperone has a more complicated interaction with substrate than previously thought. 
 
3.3.3 DNAJA1 and DNAJA2 have nearly identical binding sites on luciferase 
We found that DNAJA1 and DNAJA2 had nearly identical binding patterns, both in 
peptide identity and relative intensity (Figure 3.3A). Thus, the functional differences 
between these co-chaperones are not due to their ability to bind to distinct sites. 
Interestingly, our studies using glass slides revealed additional binding sites for DNAJA1 
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beyond those originally identified using cellulose arrays [62]. Both studies identified strong 
luciferase binding sites at 259-280 and 415-436 (Figure 3.3A).  
 
The binding pattern of Hsc70 was similar to those of the J proteins (Figure 3.3B), suggesting 
that these interactions may be competitive. The relative intensity of many Hsc70 binding 
sites tended to be reduced compared to the J protein signals, suggesting that its affinity may 
be weaker [65]. There were some sites unique to the J proteins, i.e. near the N- and C-
termini, but the lack of continuous series of sites suggests that these sites may be false 
positives. The five binding sites previously identified for Hsc70 [62] (19-37, 67-82, 208-223, 
433-451, and 523-538) were confirmed by our data with the exception of 67-82, though this 
region was bound by DNAJA1 and DNAJA2. In summary, our data confirms previously 
identified binding sites and identifies a number of novel interactions.  
 
3.3.4 Hsp70 influences the binding of DNAJA2 but not DNAJA1 to luciferase 
We envisioned that peptide arrays could be a good platform for understanding how 
chaperones converge on peptide substrates. For luciferase, we were specifically interested in 
whether Hsc70 might impact the binding of DNAJA1 or DNAJA2. To test this idea, we co-
incubated the J proteins with untagged Hsp70 in the presence of ATP or ADP. We repeated 
each experiment in duplicate and compared all possible pairs. We then evaluated the 
statistical significance of the changes using CyberT [66, 67]. These studies revealed that 
Hsp70 stimulated binding of DNAJA2 to a series of four peptides comprising residues 413-
439 (p < 0.05), while DNAJA1 was unaffected (Figure 3.4). This effect was not dependent 
on nucleotide (data not shown). We conclude that Hsc70 promotes the binding of DNAJA2 
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to residues 413-439 in luciferase, and DNAJA2 binding may play a particularly important 
role in productive luciferase refolding. When the binding sites were mapped onto a surface 
of folded luciferase, we found that most of the sites bound by DNAJA2 (green) are on 
surface exposed α-helices, but residues 413-439 comprise two strands of a β-sheet located at 
the interface between the two domains of luciferase (Figure 3.5). Thus, it is possible that 





3.3.5 Properties of luciferase peptides bound by Hsc70 and J proteins 
Next, we examined the physicochemical properties of the peptides bound by DNAJA1, 
DNAJA2 and Hsc70. In these studies, we examined the correlation of raw fluorescence 
with eight properties of the array peptides: aliphatic index [68], hydrophobicity (GRAVY 
score [69]), average molecular weight of amino acids, number of aromatic residues (Tyr, 
Phe, Trp), calculated isoelectric point (pI) [70], net charge at pH 7.2, number of basic 
residues (Arg, Lys), and number of acidic residues (Glu, Asp). Surprisingly, no correlation 
was observed with peptide hydrophobicity (Table 3.1). Instead, the strongest preference for 
all three chaperones was to bind bulky and aromatic residues. Additionally, a slight 
preference against aliphatic peptides was observed. While DNAJA1 and DNAJA2 did not 
exhibit any correlation with 
overall charge or charged 
residues, Hsc70 showed a 
slight preference for higher 
pI values, positive charge at 
pH 7.2, and against acidic 
residues. These results 
challenge the limited 
characterization of Hsc70 
binding sites as comprising 
a hydrophobic core flanked 
by basic residues [63]. Our 
results suggest that 
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hydrophobicity has minimal predictive value for Hsc70 and J protein binding, while side 



























3.3.6 Design of tau microarrays 
In order to determine the binding sites of chaperones on tau, another microarray was 
designed with the same principles as used in the creation of the luciferase array: 15 AA 
peptides with 4 AA steps for a total of 187 tau peptides (Appendix 3.2). Additionally, 7 
phosphomimetic peptides were designed incorporating a glutamic acid (or two) in place of 
Ser/Thr residues whose phosphorylation is known to impact chaperone interactions with 
tau (Table 3.2). The tau array encompasses peptides from the longest isoform of tau, which 
is only expressed in the peripheral nervous system (PNS) (758 AA). For this chapter, we 
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 As in the luciferase arrays, His-tagged chaperones were incubated with the tau arrays and 
fluorescence images acquired. Two sample array images are shown in Figure 3.7 to provide 
a visual comparison of the results obtained from two representative chaperones: DNAJA1 
and Hsp27. As a control, the array was incubated with a fluorescent anti-His6x antibody 
alone and positive labeling was excluded from future analyses (red squares in Figure 3.7). 






3.3.7 Map of chaperone binding sites on tau 
Using the tau peptide microarrays, we have mapped the binding of 17 chaperones (Figure 
3.8). These results provide an unprecedented examination of the binding of chaperones to a 
single protein substrate and a number of initial observations are striking. 
 
First, the binding sites on tau were relatively short and most were only composed of three to 
four consecutive peptides. Thus, the “footprints” of chaperone interactions with tau were 
smaller and more localized than the binding sites on luciferase. This difference might arise 
from the fact that tau is an intrinsically disordered, highly soluble protein that does not have 
a globular core. Thus, unlike luciferase, it does not require broad chaperone binding in the 




Another feature of this map is that there appear to be a limited set of “hotspots” for 
chaperone interactions. For example, the extreme N-terminus of tau was a binding site for 
the J proteins, Hsp72 (but not Hsc70), BAG1, FKBP51, and the E2 ubiquitin conjugating 
enzymes Ube2w and UbcH5B. The N-terminus of tau has recently emerged as an important 
region for normal function and it has been implicated in the pathological cascade of tau 
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aggregation. Our data suggest that chaperones may be involved in regulating these 
functions, which is a possibility that has not been appreciated previously. Other “hotspots” 
included a portion of the proline-rich domain immediately upstream of R1, the 
275VQIINKK281 motif in R2, and a section of the C-terminal region including several 
phosphorylation sites. The possible implications for these interactions will be discussed 
below. 
 
Peptide 228 (228VVRTPPKSPSSAKSR242) in the proline-rich domain emerged as a binder for 
the majority of the chaperones tested and it was often the brightest spot on the array. This 
peptide includes half of the 225KVAVVRT231 motif, which is involved in microtubule binding 
and transiently occupies β structure in solution [71-73]. It also contains a PXXP motif 
(233PKSP236), which act as interaction sites for the SH3 domains of Src family tyrosine 
kinases [74] and a region, 232PPKSPSSA239, that transiently occupies polyproline II helical 
structure [72]. Moreover, this peptide encompasses four residues that have been found to be 
phosphorylated in AD (Thr231, Ser235, Ser237, and Ser238) [37]. Phosphorylation of 
Thr231 and Ser235 impairs microtubule binding [35, 75], suggesting an important interplay 
between microtubule interactions, chaperone binding and post-translational modifications. 
Finally, this sequence contains the binding site of the peptidyl-prolyl isomerase Pin1 
(231TPPKSP236 with Thr231 phosphorylation required), which induces a conformational 
change in tau that promotes its binding to microtubules [37, 76, 77]. This region of tau is 
involved in many different interactions and our findings provide evidence that chaperones 
might be involved in further regulating these contacts. Further validation by other 
biophysical methods, such as NMR and ITC, will be required to further explore this 
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possibility. Nevertheless, intriguing (and hypothesis building) possibilities are suggested by 
closer examination of the peptide array results and the following sections focus on the 




3.3.8 Tau binding sites for the “core” chaperones: Hsp72, Hsc70 and Hsp90 
Our lab has previously reported binding sites for Hsp72 and Hsp90 on tau [48]. In that 
study, we found that Hsp72 had four binding sites on tau, two of which were shared with 
Hsp90, while Hsp90 had no unique binding sites. In an ELISA binding assay, Hsp72 was 
able to compete with Hsp90 for tau binding, but Hsp90 was unable to compete with Hsp72, 
providing supporting evidence for the array data. The present work refines the array findings 
and introduces results for Hsc70, the constitutively expressed isoform of Hsp72. 
 
The intensity values for representative Hsc70 and Hsp72 experiments are shown in Figure 
3.9. For clarity, only peptides corresponding to the 4R2N isoform of tau are shown in the 
graph. Each experiment was replicated 2 to 3 times, and these replicates informed the 
selection of the reproducible binders reported in Figure 3.8. When the data is viewed in this 
way, it is readily apparent that the binders vary widely in intensity. Features of some of the 
binding sites are highlighted in Figure 3.9C. 
 
3.3.9 Hsp72 binds a microtubule-binding site upstream of the repeat domain 
Hsp72 bound to three peptides spanning residues 220-242 (Figure 3.9B). The region 220-242 
is located in the proline-rich domain upstream of the repeats. It includes the 225KVAVVRT231 
motif, which has β−structure 18% of the time [72] and is one of four regions that interact 
with microtubules [71, 72]. Thus, the interaction of Hsp72 with this region may play a 




In contrast to Hsp72, Hsc70 bound relatively weakly to this region, especially the upstream 
residues. This result suggests that Hsc70 may not interact directly with the 225KVAVVRT231 
motif. However, it retained some affinity for the polyproline helix, 232PPKSPSSA239 and 
phosphorylated residues Thr231, Ser235, Ser237, and Ser238 (as discussed in Section 3.3.7). 
We have recently found that Hsc70 and Hsp72 have distinct effects on tau stability [57] and 
these array findings suggest that the binding to the KVAVVRT region may be involved in 
this difference. 
 
3.3.10 Hsc70 binds 275VQIINKK281, a hexapeptide involved in PHF formation 
The strongest binding site for Hsc70 was the two peptides spanning residues 264-282 in the 
repeat domain. These peptides were not bound by Hsp72 or Hsp90, which is interesting 
because Hsc70 has been implicated in restoring tau binding to microtubules, while Hsp72 
and Hsp90 are linked to tau degradation. The 264-282 region comprises the end of R1, 
including the characteristic PGGG motif found in all four repeats, and the beginning of R2, 
including 275VQIINKK281. The shared residues between the two peptides are 
268HQPGGGKVQII278. Interestingly, Hsc70 did not bind peptide 272 (which immediately 
follows these two peptides) even though it includes the full 275VQIINKK281 motif, which 
could mean that Hsc70 binding of this motif requires additional upstream residues. This 
requirement was not tested by Sarkar and coworkers, as their work demonstrated the 
necessity of the VQI(I/V) motif and not its sufficiency [52]. Thus, additional studies will be 
required to better understand these interactions. This part of tau, especially the 
275VQIINKK281 motif (dubbed PHF6*), is important for function and it is involved in 
microtubule binding, heparin binding, and forming the core of PHFs [54, 55]. The 
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interaction of Hsc70 with this region thus likely plays an important regulatory role, perhaps 
allowing Hsc70 to control the interacting partners of tau. Another important feature of this 
region is that it is contains four mutations linked to FTDP-17 [34]. Three of these mutations 
are L266V, G272V and N279K, all of which cause increased tau aggregation and 
moderately reduced microtubule assembly competence [34, 78]. Interestingly, while G272V 
binds normally to microtubules, N279K exhibits dramatically attenuated binding, 
suggesting different mechanisms for disregulation by these two mutations [78]. Another 
mutation in this region is ∆K280, which is associated with dramatically enhanced tau 
aggregation and reduced microtubule affinity [78, 79]. Additionally, K280 has been 
identified as the primary target of acetylation, a post-translational modification that appears 
to be used to dynamically regulate tau [80, 81]. Ac-K280 tau has significantly reduced 
affinity for microtubules and is strongly correlated with pathological tau PHFs [81]. Thus, 
our results suggest that Hsc70 may compete with acetyltransferases and act as one of the 
regulators of tau acetylation. 
 
3.3.11 Hsc70 binds a C-terminal region rich in phosphorylated residues 
Another strong binding site for Hsc70 is the region 388-402, which only weakly bound to 
Hsp72. This C-terminal site is located adjacent to the repeats and it contains three residues 
that have been found to be phosphorylated in AD brains: Tyr394, Ser396 and Ser400 [37]. 
Tyr394 phosphorylation is only found in PHFs isolated from AD brain, not soluble tau from 
healthy brain [82-84]. Phosphorylation at Ser396/Ser404 comprises the epitope of an 
antibody called PHF-1 and has thus been extensively used as a marker of 
hyperphosphorylated tau [85]. In vitro studies have found that phosphorylation at 
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Ser396/Ser404 leads to increased tau aggregation [75, 86-88]. Furthermore, tau 
phosphorylated at S396/S404 is targeted for chaperone-mediated proteasomal degradation 
[89]. Interestingly, neither Hsc70 nor Hsp72 bound the phosphomimetic peptide P6, which 
is the same as peptide 388-402 except for a S396E mutation (see Table 3.2). This result 
suggests that Hsc70 might only associate with this section of tau only when Ser396 is 
unphosphorylated, though the effect of phosphorylation of the other residues in this region 
is unknown. Secondly, this peptide includes the site of a mutation associated with FTDP-17, 
G389R [34, 90].  This mutation impairs microtubule binding, but its effect on in vitro 
aggregation has not been determined [34]. Thirdly, the peptide includes the motif 393VYK395, 
which was found to be able to form fibrils in isolation and it also enhanced the aggregation 
of the PHF6 and PHF6* peptides [91]. This sequence is likely the nucleating region that 
allows the C-terminal tail of tau to form straight filaments in isolation from the rest of tau 
[92]. However, the mutation Y394K in the context of 4R2N tau did not affect the kinetics of 
PHF formation, suggesting that this motif is not directly involved in the aggregation of full 
length tau [91]. Nevertheless, its similarity with the known Hsc70 binding site, 
306VQIVYK311, may form the basis of Hsc70’s interaction with this binding site. It is known 
that the C-terminus of tau interacts with the repeat domain, forming part of the “paperclip” 
conformation [93], so interaction of Hsc70 with the bending region may serve as a handle to 
control this intra-molecular interaction. Deleting this region of tau (392-421) blocks the 
ability of an N-terminal fragment of tau (1-196) to inhibit the polymerization of full-length 
tau, suggesting that interactions between the N-terminus and this C-terminal region may 




3.3.12 Hsp90 has no unique binding sites 
The binding spots for Hsp90 are overlapping with those of Hsp72, spanning residues 224-
242 and thus including the 225KVAVVRT231 and 232PPKSPSSA239 motifs and the 
phosphorylated residues Thr231, Ser235, Ser237, and Ser238 (Figure 3.10). Therefore, 
Hsp90 has no unique binding sites on tau and may interact with tau only after it is “handed” 




3.3.13 Distinct binding patterns of Hsc70, Hsp72, and Hsp90 reflect functional 
differences 
The marked differences in the binding sites for Hsp72 and Hsc70 may partially explain the 
functional differences in how the chaperones regulate tau homeostasis. Association of 
Hsc70 with tau is increased after microtubule destabilization, suggesting that Hsc70 
preferentially interacts with free tau [95]. Recent work has shown that over-expression of 
Hsc70 favors tau accumulation, while Hsp72 causes increased tau clearance through 
proteasomal degradation [57]. Interestingly, this work also found that Hsc70 and tau were 
strongly synergistic for microtubule assembly, while Hsp72 did not have this effect [57]. 
Chimeras between Hsc70 and Hsp72 confirmed that the functional differences were 
determined by the identity of the C-terminal domain of the Hsp70 family members. 
Consistent with this finding, the Hsp72-tau complex was able to recruit the E3 ubiquitin 
ligase CHIP while Hsc70-tau was not. Further, our recent studies suggest that the Hsp72-tau 
complex converts to an Hsp90-tau complex during chemically-induced degradation of tau 
[48]. As discussed in Chapter 1, CHIP binds the C-terminus of Hsp70 and Hsp90 family 
members. Thus, our array findings suggest that differences in the chaperone-binding sites 
(and possibly their affinities) direct tau to its various fates: binding to microtubules or being 
shuttled to the proteasome for degradation. 
 
3.3.14 J proteins bind both shared and distinct regions of tau 
The binding of four J proteins to tau was evaluated using the microarrays (Figure 3.8). 
DNAJA1 and DNAJA2 had strikingly similar binding patterns, much as they did on the 
luciferase microarrays. The only discrepancy was in the region 25-43, but the functional 
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significance of this difference is not known. DNAJB1 and DNAJB4 each shared some 
binding sites with the Class A J proteins and each other, but also had unique binding sites. 




3.3.15 J proteins bind the N-terminus of tau, a crucial structural and functional element 
A striking feature of these results is that all four J proteins bind the extreme N-terminus of 
tau (Figure 3.8). Specifically, DNAJA1, DNAJA2 and DNAJB4 bind the second and third 
peptides, spanning residues 5-23, while DNAJB1 binds 5-19. In addition, DNAJA2 and 
DNAJB1 bind a second region from 25-43 (Figures 3.11 and 3.12). The overlap between the 
peptides suggests that the two binding sites include 5RQEFEVMEDHAGTYG19 (all four J 
proteins) and 29QDQEGDTDAGL39 (DNAJA2 and B1). These two neighboring sites might 
afford two “handles” for J proteins to bind tau. These events might occur in concert with 
Hsp72, because this chaperone also bound these two sites (Figure 3.9B). 
 
The interaction of J proteins with the N-terminus of tau is intriguing because this region has 
been implicated in its function, structure, regulation, and pathology. Two mutations in this 
region, R5H and R5L, have been identified in cases of FTDP-17 and PSP [33, 96, 97]. The 
R5L mutation causes increased tau fibrillization and longer filaments [98, 99]. On the other 
hand, deletion of residues 2-18 results in drastically slowed in vitro tau fibrillization with a 
concomitant decrease in fibril length [98]. R5L also inhibits retrograde axonal transport by 
disrupting the interaction between tau and the dynactin complex [100]. Two caspase 
cleavage sites have been reported that result in a truncated N-terminus: caspase-6 cleaves 
after Asp13, while an unknown caspase may cleave after Asp25 [41, 101, 102]. Loss of the 
N-terminus is observed during later stages of AD progression and correlates with caspase-3 
cleavage of the C-terminus at Asp421 [101]. Based on these observations, current models of 
tau processing suggest that cleavage of the N-terminus may reflect an attempt at self-
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protection by the cell. Thus, binding of J proteins to this site might help regulate the timing 
and extent of the cleavage events.  
 
Although tau is a natively unstructured protein, a growing body of evidence demonstrates 
that parts of the protein adopt a discrete set of conformations [72, 93]. Importantly for this 
discussion, the N-terminus is directly involved in these conformations. The major 
conformation occupied in solution is termed a “paperclip” and was deduced from FRET 
measurements [93]. The paperclip consists of the C-terminus folded over to interact with the 
repeat domain, while the N-terminus folds over to interact with the C-terminus (but not the 
repeat domain) [93]. Additionally, conformation-specific antibodies have been discovered 
that recognize discontinuous epitopes, and some of these epitopes include the N-terminus. 
For example, the MC-1 and Alz-50 antibodies both have epitopes that include the N-
terminus and R3 [103, 104]. These antibodies recognize tau in early AD pathology but not 
healthy brains, and can recognize soluble tau that is competent for PHF formation, 
suggesting that the N-terminal interaction with the repeat domain represents an early step in 
neurotoxic tau aggregation [105]. Furthermore, FRET studies found that a mutant form of 
tau including 7 Glu residues in place of known pathological Ser/Thr phosphorylation sites 
adopted a compacted form of the paperclip conformation, including the N-terminus 
approaching the repeat domain, and exhibited dramatically increased reactivity to the MC-1 
antibody (though not Alz-50) [106]. These findings provide a possible structural link 
between known pathological phosphorylation events and the increased propensity of 




In addition to its involvement in structure of tau, the N-terminus has been directly 
implicated in mechanisms of neurotoxicity. One study found that filamentous, but not 
soluble, tau can inhibit anterograde (kinesin-dependent) fast axonal transport (FAT) [107]. 
A soluble N-terminal fragment of tau was able to recapitulate this inhibition, and the effect 
required residues 2-18, suggesting that this part of the N-terminus becomes exposed upon 
fibril formation and is then available to inhibit FAT [107]. The same group later found that 
residues 2-18 constitute a phosphatase activating domain (PAD) that directly activates 
protein phosphatase 1 (PP1), which in turn activates GSK3, causing phosphorylation of 
kinesin and anterograde FAT inhibition [108]. Many of the pathological signatures of AD 
are consistent with FAT inhibition, suggesting that this toxic gain-of-function upon tau 
aggregation could constitute a major mechanism of pathology [108]. Interestingly, both 
Hsp72 and phosphorylation of the N-terminus (pTyr18) have been found to prevent c 
inhibition by tau, suggesting that this interaction is regulated by post-translational 
modifications and the chaperone machinery [109, 110]. Tau toxicity in primary neuronal 
cultures has been traced to arise from residues 26-44, which cause NMDAR-dependent 
excitotoxic cell death [111]. This mechanism of toxicity also involves activation of 
extracellular regulated kinases (ERK1/2) and calpain, which in turn causes cleavage of tau 
to a 17 kDa fragment that may correlate to residues 45-230 [111]. The dramatic and 
complicated neurodegeneration that follows tau aggregation may result from some 
combination of these effects, which notably arise from neighboring but non-overlapping 




The N-terminus is also subject to post-translational modifications. Tyr18 is a target for 
phosphorylation by the tyrosine kinase Fyn, and it has been shown that phosphorylation of 
this residue is important for interaction with the SH2 domain of Fyn itself [37, 112]. Of the 
four Tyr residues subject to nitration by peroxynitrite (ONOO−), Tyr18 and Tyr29 are 
preferentially nitrated [113]. Nitration of Tyr18 dramatically reduces the rate and amount of 
fibrillization, while nitration of Tyr29 has a moderate effect on rate and results in longer 
fibrils formed [114]. Tau nitration occurs during the course of AD and other tauopathies 
[115] and, specifically, nitrated Tyr29 has been detected in tau from diseased brains but not 
normal controls [116].  
 
This body of research demonstrates that the N-terminus of tau may play a central role in the 
pathology of AD and other tauopathies. Our studies suggest that J proteins may have a 
unique role in regulating the N-terminus of tau and its many interactions. This hypothesis is 
supported by the finding that over-expression of DNAJA1 promotes degradation of tau 
independently of Hsp70 [50]. Thus, we hypothesize that J protein binding to residues 5-19 
may inhibit the activation of PP1 and the consequential inhibition of FAT. Similarly, 
binding to 29-39 may prevent activation of extrasynaptic NMDARs and excitotoxic 
signaling. These interactions could also compete with, or be inhibited by, post-translational 
modifications (phosphorylation and nitration). Based on their binding to the N terminus, J 
proteins could also modulate the conformations of tau. It is known that DNAJA1 
expression is 47% reduced in AD brains [50], perhaps creating a dis-equilibrium in the types 




3.3.16 Class A J proteins bind the repeat domain and C-terminus of tau 
Other than the minor variation between DNAJA1 and DNAJA2 in binding the N-terminus, 
the two J proteins have identical binding sites in the rest of the protein. This shared binding 
pattern is also highly similar to that of Hsc70, which may indicate cooperation between the 
constitutive Hsc70 and the class A J proteins. These binding sites include peptide 228, the 
two peptides encompassing the 275VQIINKK281 motif, and peptide 388, which contains three 
phosphorylation sites. Like Hsc70, DNAJA1 and DNAJA2 did not interact with P6 
containing the Ser396 phosphorylation mimic, further suggesting that phosphorylation of 
this region may inhibit chaperone interactions. Unlike Hsc70, DNAJA1 and DNAJA2 both 
bound peptide 380-394, immediately upstream of the phosphorylation-rich region. The only 
functional connection identified for this region is that the first four residues comprise the 
end of a heparin-binding region, 372-383, identified by NMR (Mukrasch 2007). It is unclear 
what functional relevance this binding site may have for J proteins, though it may serve as 
an anchoring site for class A J proteins through which they can recruit Hsc70. 
 
3.3.17 Class B J proteins have distinct binding sites throughout the length of tau 
Beyond the N-terminus, DNAJB1 and DNAJB4 bind distinct sites on tau (Figure 3.12). The 
most robust binding site for DNAJB1 is residues 220-242, which is also a binding site for 
Hsp72 and Hsp90 (see Section 3.3.7). DNAJB1 has a unique binding site in the region 
between the N-terminal inserts and the proline rich domain, peptides 105 and 113. The 
discontinuous nature of these peptides makes it difficult to draw conclusions about the 
presence of a single site or two discrete sites. This region encompasses two known  
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phosphorylation sites – S113 and T123 – and a region (114LEDEAAGHVT123) that has alpha 
helical character by NMR [37, 72]. 
 
DNAJB4 binds strongly to peptide 69-83, spanning the end of N1 and the beginning of N2, 
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which is a region that was not identified for any other chaperone (Figure 3.8). This peptide 
includes two known phosphorylation sites – Ser69 and Thr71 – but its role in tau biology is 
not clear. DNAJB4 also weakly binds three peptides in the repeat domain, 308, 316, and 
320, encompassing residues 308-334 which correspond with most of R3. R3 has been found 
to interact with the N-terminus, and this interaction comprises the MC-1 conformational 
epitope that signals an early pathological form of tau [103, 104, 106]. DNAJB4 may 
therefore be able to regulate this interaction. Additionally, this section of R3 contains three 
mutations identified in cases of FTDP-17 (L315R, K317M, and S320F), while an additional 
three mutations occur immediately downstream (G335V, Q336R, V337M), underscoring 
the importance of R3 in tau function and pathology [34]. 
 
Finally, DNAJB4 interacts with two C-terminal peptides, 380 and 388, which are also 
bound by the two class A J proteins tested. Interestingly, DNAJB4 was the only chaperone 
to bind the phosphomimetic peptide P6 (S396E). This suggests that DNAJB4 may be able to 
interact with tau even when it is phosphorylated, distinguishing it from other chaperones. 
This finding needs to be expanded to investigate other phosphorylation sites within 
DNAJB4’s binding sites on tau – Ser69, Thr72, Tyr394, Ser400, and combinations thereof. 
  
3.3.18 BAG1 binds multiple regions of tau rich in residues phosphorylated in AD 
As discussed in Chapter 1, the BAG proteins are co-chaperones of Hsc70/Hsp70 that 
facilitate nucleotide and substrate release. In neuronal cell culture, BAG1 promotes 
accumulation of tau, an effect that is accentuated by Hsp70 induction, and in the absence of 
BAG1, tau is degraded by the proteasome [117]. One of the three BAG1 isoforms, BAG1M, 
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is significantly upregulated in AD [118] and all three isoforms of BAG1 interact with tau in 
an Hsc70-dependent manner [117]. Further, a direct interaction between BAG1 and tau has 




On our tau microarray, BAG1 has a unique binding pattern relative to other chaperones, 
but its individual binding sites are all shared with at least one other chaperone (Figure 3.8). 
A plot of the intensities reveals that the strongest binding sites are 264-282 (containing the 
275VQIINKK281 motif) and 308-330, comprising most of R3 (Figure 3.13). Interestingly, 
these sites are both rich in FTDP-17 linked tau mutations, encompassing a combined 7 
mutations (L266V, G272V, N279K, ∆K280, L315R, K317M, and S320F) [34]. Other 
binding sites are mostly individual peptides and are found throughout the length of tau: the 
N-terminus (peptides 5 and 17), the proline-rich domain (peptide 184), the polyproline helix 
upstream of the repeat domain (peptide 228), and the C-terminus (peptides 380 and 388). 
BAG1 did not bind P6 despite binding 388, suggesting the interaction may be inhibited by 
phosphorylation. The functional significance of all of these binding sites has been discussed 
above, with the exception of peptide 184. This peptide falls between the two stretches of 
PXXP motifs responsible for interactions with the SH3 domains of kinases. It is rich in 
residues that undergo phosphorylation in AD, including Ser184, Ser185, Ser191, Tyr197, 
and Ser198. Interestingly, BAG1 knockdown leads to hyperphosphorylation of the tau that 
escapes proteasomal degradation, suggesting that BAG1 may play a role in regulating tau 
phosphorylation [117]. Our data suggests that, as BAG1 binds multiple regions rich in AD-
related phosphorylation targets, part of this role could be competing with kinases for binding 
to their target residues in both the proline-rich domain and the C-terminal domain.  
 
The binding of tau by two other BAG proteins, BAG2 and BAG3, was investigated using 
the microarrays. Unfortunately, the insolubility of BAG2 prevented definitive conclusions 
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(Figure 3.13), but some weak binding was observed at residues 264-282 and 308-330 in the 
repeat domain. BAG3 was soluble and it clearly did not bind tau.  
 
The shared binding sites of BAG1 and BAG2 are intriguing since they have opposing roles 
in the regulation of tau. While BAG1 overexpression causes tau accumulation, BAG2 
overexpression promotes proteasome-mediated, but ubiquitin-independent, degradation of 
tau, particularly aggregated and phosphorylated tau [119]. Furthermore, BAG1 and Hsc70 
associate with free tau in the cytosol, while BAG2 and Hsc70 form a complex with tau on 
the microtubule [117, 119]. The shared binding sites for BAG1 and BAG2 could allow for a 
balance between these two opposing regulatory mediators.  
 
3.3.19 FKBP51 and FKBP52 have markedly different tau binding profiles 
FKBP51 and FKBP52 are immunophilins important for immune cell activation [120, 121]. 
These proteins also interact with Hsp90 through their TPR domains and have peptidyl-
prolyl cis-trans isomerase (PPIase) activity. Both have been implicated in the regulation of 
tau, but despite their high homology, they appear to have opposing roles, much like BAG1 
and BAG2 [122]. FKBP51 stabilizes tau by preventing ubiquitination and promoting 
dephosphorylation [123]. FKBP52 prevents tau accumulation and antagonizes microtubule 
assembly, while FKBP51 and tau have synergistic effects on microtubule assembly [123-
125]. Both directly bind tau in the absence of other chaperones [123, 125]. The PPIase 
domain of FKBP51 has been shown to isomerize proline residues in tau, but the functional 
role of FKBP52’s PPIase domain has not been demonstrated [123]. Because of the 
 
 93 
intriguing roles of these chaperones in tau regulation, they were both tested on the tau 
microarray. 
 
FKBP51 and FKBP52 had very different binding patterns (Figure 3.14). While FKBP51 
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bound eight different regions on tau, FKBP52 bound a single peptide in the proline-rich 
region. The peptide bound by FKBP52, which was also bound by FKBP51, was peptide 228 
(see Section 3.3.7) and this interaction has been confirmed by NMR (Chad Dickey, personal 
communication). This finding further suggests that residues 228-242 in tau constitutes a 
central regulatory handle for the chaperone network. 
 
In contrast to FKBP52, FKBP51 bound sites throughout the length of tau. Its binding 
pattern was strikingly similar to that of BAG1 (Figure 3.8), which is especially interesting 
given that both co-chaperones stabilize tau. The strongest site for FKBP51 binding was near 
the N-terminus at residues 5-23. The other binding sites included peptide 184 in the 
polyproline rich region (a binding site shared only with BAG1), 264-282 (beginning of R2), 
296-330 (all of R3), 344-358 (within R4) and peptides 380 and 388 (C-terminus). While 
BAG1 also bound 308-330, the FKBP51 binding site is longer, extending to include 296-308 
and thus the full 306VQIVYK311 motif. This segment is also the site of six FTDP-17 mutations 
(∆N296, N296H, P301S, P301L, G303V, S305N) [34]. Combined with the 7 mutations 
bound by BAG1 (see above), a mutation in peptide 388 (G389R), and two mutations near 
the N-terminus (R5L and R5H), FKBP51 binds a total of 16 FTDP-17 mutation sites, a 
significant portion of the ~40 known tau gene mutations. This result suggests that FKBP51 
binding to tau may be impaired in many tauopathies, perhaps contributing to pathology. 
  
While most of the FKBP51 binding sites were shared with BAG1, residues 344-358 were 
unique to FKBP51. This peptide contains a KXGS phosphorylation site, Ser 356; 
phosphorylation of this residue blocks microtubule binding and provides resistance to 
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chaperone-mediated degradation (see below) [89, 126]. This region also contains one of the 
motifs recognized by Hsc70 for chaperone-mediated autophagy, 347KDRVQ351, though 
binding of this site by Hsc70 was not observed in our experiments [56]. Thus, FKBP51 
might serve as a handle for Hsc70-mediated recognition of tau for autophagy. FKBP51 
shares this binding site with the degradation chaperones (CHIP, Ube2w and UbcH5, see 
below) suggesting a competition between the pro-stabilizing and pro-degradation arms of 
the chaperone machine. 
 
3.3.20 CHIP, UbcH5B, and Ube2w cooperate to ubiquitinate tau in AD 
The E3 ubiquitin ligase CHIP and the E2 ubiquitin-conjugating enzyme UbcH5B, in 
cooperation with the constitutive Hsc70/Hsp90 chaperone machinery, have been identified 
to play a key role in the processing of tau [127-129]. Tau lesions in various tauopathies are 
immunoreactive for ubiquitin [130]. Additionally, tau extracted from AD brain can be 
ubiquitinated in vitro by CHIP and UbcH5B, but tau from healthy brain cannot [127]. This 
disparity was traced to the phosphorylation state of tau; specifically, tau phosphorylated at 
proline-directed residues (by GSK3B and Cdk5; e.g. Ser202, Ser205, Ser396, and Ser404) 
can be ubiquitinated, while unphosphorylated tau cannot [47, 127]. However, tau 
phosphorylated at KXGS motifs (pS262/S356) is resistant to chaperone-mediated 
proteasomal degradation [89]. Interestingly, CHIP overexpression is protective against cell 
death caused by hyperphosphorylated (proline-directed) tau [127]. Inhibition of the 
proteasome along with tau, GSK3B, and CHIP co-expression causes accumulation of 
aggregates containing ubiquitinated hyperphosphorylated tau; however, these aggregates are 
not cytotoxic, suggesting that ubiquitination and sequestration of tau into aggregates may 
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constitute a protective mechanism. Indeed, deletion of CHIP in mice causes the 
accumulation of soluble, hyperphosphorylated, non-ubiquitinated tau, but no aggregates 
ever form, even when P301L mutant tau is expressed, suggesting that ubiquitination is a 
necessary signal for tau aggregate formation [89]. Misregulation or decay of this system may 
be an important pathological event. 
 
CHIP directly interacts with tau, though neither the U-box or TPR domains of CHIP are 
sufficient for this interaction, suggesting that CHIP may engage in a multivalent interaction 
with tau [128]. Attempts at mapping the CHIP binding site(s) on tau found that CHIP 
interacted best with tau(156-373), encompassing the proline-rich domain and the repeats, 
while CHIP was also able to bind tau(249-441) [128]. CHIP binding of tau is abrogated by 
MARK phosphorylation of S262/S356 or mutation of these residues to alanine, which 
could suggest that the hydroxyl side chains of the Ser residues are themselves important, 
either for direct interaction with CHIP or maintaining a tau conformation conducive to 
CHIP binding [47]. 
 
Tau immunoprecipitated from AD brain by the MC-1 antibody has been found to be poly-
ubiquitinated at three lysines in the repeat domain (K254, K311, K353) (Figure 3.15, pink 
dots) [131]. Notably, K353 is very close to one of the MARK phosphorylation sites, S356. 
In order to determine whether UbcH5B has site-selectivity for ubiquitination of tau in the 
absence of CHIP, tau was incubated in vitro with UbcH5B for 18 hours; this tau was found 
to be ubiquitinated at no less than 17 lysine residues (including the three previously 
identified) scattered throughout the length of tau (Figure 3.15, purple dots) (Matthew 
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Scaglione, personal communication). This suggests that CHIP may direct UbcH5B’s activity 
towards the three lysines in the repeat domain, though the mechanism of this targeting is 
unknown. Furthermore, another E2 involved in the regulation of CHIP, Ube2w, has been 
found to specifically monoubiquitinate tau at the N-terminal amine (Matthew Scaglione, 
personal communication) [132]. Interestingly, this form of ubiquitinated tau is unable to 
form aggregates, suggesting that the two different types of ubiquitination may have 
functional differences in vivo, thus providing an explanation as to why two separate E2s are 
used. We investigated the binding of CHIP, UbcH5B, and Ube2w to the tau microarray to 
determine to what extent binding site(s) might contribute to the differential tau ubiquination 
activity of these two E2-E3 pairs. 
 
3.3.21 E2s cooperate with CHIP and compete with stabilizing co-chaperones 
The E2 ligases Ube2w and UbcH5B had strikingly similar binding patterns on the tau array 
(Figure 3.15). This finding suggests that binding sites alone cannot account for the disparate 
tau ubiquitination carried out by these E2s and that some other variable must affect site 
selectivity, perhaps other proteins or the conformational state of tau. The strongest binding 
site for both is peptide 228-242 in the proline rich region, which is just upstream of one of 
the AD ubiquitination sites, K254. They also both interact with the N-terminus at the sites 
identified for J proteins and FKBP51, 5-23 and 25-43. Furthermore, both have nearly the 
same pattern of rather weak binding to various sites in all four repeats of the repeat domain 
and the C-terminus. The only marked difference between the two E2s is that UbcH5 has 
two unique binding sites in the N-terminal half of tau: 49-67 and 97-124. Neither of these 
sites was identified for any other chaperone save for some overlap with DNAJB1 in the 
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latter site. The functional role of these sites is not clear as they do not include lysines 
ubiquitinated either by UbcH5B alone or in AD tau, but they may allow UbcH5B to interact 





The E3 ligase CHIP had a markedly different interaction pattern from the E2s (Figure 3.16). 
It bound two peptides, 37-51 and 143-154, with high intensity in three experimental 
replicates. Neither is identified for any other chaperone in our dataset. Peptide 37 does not 
have distinguishing features beyond a single phosphorylated residue, S46, but given the 
general importance of the N-terminus in tau biology (see Section 3.3.15), this binding site 
could have an important role in regulating tau. Peptide 143 comes with a caveat: this 
peptide on the array begins with three residues from the PNS isoform of tau, and the next 
peptide on the array, which also contains the full 143-154 sequence, was not bound by 
CHIP, suggesting that this interaction could be an experimental artifact. If it is a genuine 
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CHIP binding site, this sequence is interesting because it contains a recently identified tau 
mutation, A152T, linked with increased risk for FTDs and AD [133]. This mutation causes 
significant impairment in microtubule assembly but, unlike most other tau mutations, 
slightly attenuates PHF formation. On the other hand, an increase in oligomer formation is 
observed, suggesting a possible toxic gain of function as oligomers are thought to be more 
neurotoxic than full filaments [36, 133]. The location of this mutation, distant from sites 
generally understood to govern MT binding and PHF formation, suggests an as yet 
unknown role for this region of tau in influencing these activities.  
 
The fact that both UbcH5B and CHIP had two unique and neighboring binding sites in the 
N-terminal projection domain, a region that is largely devoid of other chaperone 
interactions, suggests that this region could act as a specific handle for ubiquination. During 
tau’s conformational switching, it is conceivable that this region could approach the repeat 
domain where AD tau ubiquitination occurs [131]. CHIP also weakly bound two regions in 
the repeat domain: 308-330 and 344-358. Notably, these two regions include two of the AD 
ubiquitination sites, K311 and K353. UbcH5 bound 288-314, also encompassing K311 but 
including the region upstream of this residue, while CHIP binding includes the region 
downstream, suggesting a possible pair of binding sites that could allow the two to 
collaborate in ubiquitination of K311. On the other hand, UbcH5 and CHIP both bound 
peptide 344 but not any neighboring peptides, suggesting a different mode of cooperation for 
ubiquitination of K353. This peptide also includes S356, one of the MARK-phosphorylated 
residues that prevents CHIP ubiquitination of tau and chaperone-mediated degradation [47, 
89]. One of our phosphomimetic peptides, P5, includes a S356E mutation; however, this 
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peptide has the same sequence as peptide 348, which was not bound by CHIP or the E2s 
either, so this cannot be taken as clear evidence that S356 phosphorylation directly blocks 
CHIP interaction; further experiments, perhaps using peptide 344, are necessary to resolve 
this question. No binding was observed to any peptides containing the other MARK-
phosphorylated residue, S262, or the corresponding phosphomimetic peptide (P4). 
 
The binding of another TPR-containing chaperone, Hop, was also tested on the tau array. 
Hop is comprised solely of TPR domains and serves to coordinate Hsc70 and Hsp90 by 
interacting with both of them simultaneously. No evidence of Hop interacting with tau has 
been reported, and indeed, we observed no binding to the array (Figure 3.8), suggesting that 
the interactions observed for CHIP, and likely the other chaperones, represent specific 
interactions. 
 
The interaction patterns of Ube2w and UbcH5B bear a striking resemblance to those of 
FKBP51 and BAG1, both of which are stabilizing co-chaperones that prevent proteasomal 
degradation of tau [117, 123] (Figure 3.8). This suggests that direct competition could 
mediate triage decisions by the co-chaperone machinery and that factors such as 
phosphorylation, conformation of tau, and other chaperones bound may determine which 
co-chaperones dominate in a given context. This data provides specific sequences within tau 




3.3.22 Hsp27 binds extensive regions of the proline-rich domain and C-terminus of tau 
Hsp27 is a member of the small heat shock protein family that preferentially interacts with 
hyperphosphorylated tau (either GSK3β treated or derived from AD brain) [51]. Hsp27 is 
regulated by phosphorylation, which alters its oligomeric state and chaperone functions. 
Delivery of wild type Hsp27 to tau transgenic mouse brains causes tau reduction and 
rescues deficits in long term potentiation (LTP), but pseudophosphorylated (3xS/D) Hsp27 
causes accumulation of tau and fails to rescue LTP [134]. From these observations, it is 
clear that the roles of Hsp27 in tau homeostasis are complex. To better understand this 
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process, we investigated the binding of Hsp27 to the tau microarray. While 
unphosphorylated Hsp27 binding to tau arrays was successful, attempts to characterize 
binding of a pseudophosphorylated Hsp27 mutant (Hsp27 (3xS/D)) were unsuccessful, 
resulting in high background and no clear signal. 
 
The binding profile we obtained for Hsp27 was broader than that for any other chaperone 
tested (Figure 3.8). The identities of these peptides were also unique relative to other 
datasets. For example, the strongest sites for Hsp27 were two long continuous stretches of 
peptides located in the proline-rich domain and part of R1 (Figure 3.17) that are largely 
devoid of other chaperone interactions. These sites were quite large and continuous, 
suggesting that Hsp27 may interact with tau in a fundamentally different way. Strikingly, 
throughout the rest of the tau sequence (R2 to the C-terminus), the binding of Hsp27 is 
almost mutually exclusive with other chaperone interactions. For example, Hsp27 did not 
bind the frequently observed binding site 264-282 (containing the 275VQIINKK281 motif) but 
bound a few peptides immediately up and downstream of this site. Furthermore, Hsp27 had 
a pronounced lack of binding to R3, a region also frequently identified for other chaperones. 
Finally, Hsp27 interacted extensively with the C-terminus from 364 onwards, where no 
other interactions have been observed. This binding profile suggests that Hsp27 might not 
directly compete with other chaperones and, further, that its binding might help maintain 
tau in a state competent for binding to other chaperones. 
 
Another unique feature of Hsp27 binding was that it bound to 4 of the 7 phosphomimetic 
peptides (Figure 3.17). These peptides included mutations mimicking phosphorylation at 
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T205, S262, S356, and S404. Hsp27 is known to interact with phosphorylated tau [51], 
which is consistent with these findings. However, Hsp27 also bound the native version of all 
of these peptides. Interestingly, two of these phosphorylation sites are proline-directed 
(T205, S404), while the others are KXGS motifs (S262, S356), suggesting that Hsp27 does 
not discriminate between the two types like the CHIP-mediated chaperone degradation 
machinery does. In fact, Hsp27 overexpression has been correlated with an increase in 
pS262 levels, an effect that could play a role in pathology by preventing tau degradation by 
CHIP [135]. 
 
Hsp27 also bound regions bearing several FTDP-17 mutations that were not bound by any 
other chaperone. Notably, Hsp27 bound all four peptides that included A152, the site of the 
A152T mutation recently identified as a risk factor for tauopathies (see Section 3.3.21) 
[133]. Hsp27 also bound regions containing four mutations in the repeat domain: three in 
R1 (K257T, I260V, and L266V) and one in R4 (K369I). All four mutations impair 
microtubule assembly and enhance aggregation [34]. Finally, Hsp27 binds peptides near the 
C-terminus containing the mutation R406W; however, this mutation has only a minor effect 
on microtubule assembly and does not enhance tau aggregation. Together, these findings 
suggest that alteration of Hsp27 binding, particularly in the proline-rich domain, may play a 





We have used a peptide microarray platform to develop the first detailed model of 
chaperones binding to tau (Figure 3.18). These results suggested that nearly the entire length 
of tau is bound by at least one chaperone. Additionally, chaperones appeared to converge 
on a limited set of "hotspots" and these locations tended to be functionally important. A 
repeating theme in these studies was that “pro-degradation” chaperones and “pro-retention” 
chaperones share identical binding sites. In particular, the stabilizing chaperones (BAG-1 
and FKBP51) and degradation chaperones (CHIP, Ube2w, UbcH5) all shared binding sites. 
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Similarly, Hsc70 (pro-stabilization) and DNAJA1/Hsp72/Hsp90 (pro-degradation) share 
some binding sites. These results suggest that competition for binding sites is one powerful 
mechanism for guiding the fate of tau in the chaperone system. Because these sites are also 
the sites of microtubule binding, post-translational modification and aggregation, the 
broader competition of chaperones for other cellular factors is likely to be central for tau 
homeostasis. These results highlight the importance of protein-protein interactions in 
protein quality control. 
 
One of the most far-reaching implications of this model is the importance of the competition 
between chaperones, tau and microtubules. In the course of normal neuronal activity, tau 
must cycle on and off of microtubules. The binding sites of Hsc70 suggest that this 
chaperone protects the aggregation-prone regions from forming aberrant interactions during 
the times when tau is free in the cytosol.   
 
Another important outcome of these studies is the interplay between chaperone binding and 
tau phosphorylation. In previous studies, Hsc70, Hsp90 and Hsp27 were all found to 
preferentially bind hyperphosphorylated tau, while CHIP only ubiquitinates tau derived 
from AD brain [47, 51, 127]. In our studies, only Hsp27 interacted extensively with the 
phosphomimetic peptides, binding 4 of 7. Generally, other chaperones didn't bind either the 
native or phosphomimetic peptides containing these residues. The exception was peptide 
388, containing Ser396, which was bound by most of the chaperones tested, while the 
corresponding phosphomimetic (P6) was never bound (except by DNAJB4). Taken 
together, these findings suggest that the preferential binding of chaperones to 
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hyperphosphorylated tau observed previously is not due to direct interactions with 
phosphorylated regions. Rather, the conformational implications of phosphorylation might 
be an important feature. Indeed, phosphorylation has been shown to directly influence tau 
conformation, with the combination of three known pathological phosphorylated epitopes 
leading to compaction of the tau "paperclip" and increased reactivity with the MC-1 
antibody [106]. Interestingly, tau incubation with Hsc70 in vitro leads to development of the 
MC-1 conformation, while MC-1 tau is one of the types preferentially degraded by 
upregulation of the chaperone machinery [89, 95]. Therefore, it appears that 
hyperphosphorylation of the whole tau molecule, not phosphorylation of individual 
residues, is important in regulating chaperone interactions. Peptide arrays do not permit 
insight into this particular question, so additional studies will be required. 
 
One exception to this model may be MARK phosphorylation at the KXGS motif containing 
Ser356. Tau phosphorylated by MARK is resistant to chaperone-mediated degradation [89]. 
One of the three ubiquitination sites identified in PHF tau from AD brain, K353, is actually 
a part of this KXGS motif. We find that a peptide containing this motif, 344-358, is bound 
by the E3 ubiquitin ligase CHIP, the E2 ubiquitin conjugating enzymes Ube2w and UbcH5, 
and the tau stabilizing co-chaperone FKBP51. These chaperones must therefore compete 
with MARK for binding to this region of tau. Phosphorylation of Ser356 may directly 
inhibit CHIP and/or UbcH5 interaction with this site, thus preventing ubiquitination and 
proteasomal degradation. Alternatively, Ser356 phosphorylation may promote the 
interaction of FKBP51 with this site, also preventing CHIP binding and ubiquitination. Our 
data does not provide specific evidence for or against these hypotheses, as the 
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phosphomimetic peptide containing S356E corresponds with peptide 348, which was not 
bound by any chaperone. Further experiments are necessary to measure the relative 
affinities of the different chaperones for peptide 344-358, determine the minimal binding site 
in this region, and evaluate the effect of Ser356 phosphorylation. 
 
The use of peptide microarrays to investigate chaperone binding to tau has allowed us to 
examine specific interactions in the absence of confounding variables such as tau 
phosphorylation, conformation state, and other interacting partners. Therefore, this dataset 
likely represents a "maximum" interaction profile that is limited and controlled by many 
other variables in vivo. This profile provides a starting point for investigations using targeted 
point mutations and deletions within tau to elucidate the relative contribution of different 
interactions in various contexts. The regulation of tau by chaperones may provide a 
valuable therapeutic opportunity, and a more detailed understanding of the interactions 
involved will allow for more rational development of selective therapeutic agents. 
 
3.5 Experimental Methods 
3.5.1 Protein Purification 
Hsp70s (DnaK, Hsc70, Hsp70, NBD constructs; Hsp70 NBD (1-383), Hsc70 NBD (1-383), 
and Hsc70 NBD+linker (1-394)) were purified as previously described [136]. Likewise, 
Hsp90, J-domain (1-108), and DnaJ were purified as previously described [136, 137], with 
the addition of a Superdex 200 size exclusion column (GE Healthcare, Pittsburg, PA) as the 
last step of the J-domain purification. N-terminal His6x-tagged DNAJA1, DNAJA2, and 
DNAJB1 were purified as previously described [10]. Hsc70SBD (394-540) was expressed in 
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BL21 cells from a pMCSG7 vector encoding an N-terminal His6x tag under ampicillin 
selection. Cells were lysed by sonication into His6x-binding buffer (50 mM Tris pH 8.0, 10 
mM imidazole, 500 mM NaCl, protease inhibitors) and purified using Ni-NTA resin 
(Novagen, Darmstadt, Germany). Protein was eluted with His6x-elution buffer (50 mM 
Tris, 300 mM imidazole, 300 mM NaCl), 2 mM EDTA added, and protein concentrated to 
~6 mg/mL.  Protein was further purified on a HiLoad Superdex 75 16/600 size exclusion 
column into storage buffer (50 mM Tris, 250 mM NaCl). Pure fractions were combined, 
concentrated, flash frozen and stored at -80oC. Hsp27, Hsp22, αB crystallin,  
expressed in Rosetta cells using the pMCSG7 vector. Cells were lysed by sonication into 
lysis buffer (20 mM Tris pH 8.0, 100 mM NaCl, 6 M urea, 5 mM β-mercaptoethanol, 15 
mM imidazole) and purified by standard denaturing his purification using Ni-NTA resin. 
Proteins were eluted with 150 mM imidazole. Following elution EDTA was added to 5 mM 
and protein was concentrated to ~20 mg/ml. Protein was refolded upon injection on a 
Superdex 200 size exclusion column (GE Healthcare, Pittsburg, PA) with refolding buffer 
(20 mM NaPi  pH 7.2, 100 mM NaCl).  The protein was flash frozen and stored at -80 oC. 
Finally, FKBP51 was purified by using a standard His purification with Ni-NTA resin 
(Novagen) followed by separation using a superdex 200 size exclusion column in (10mM 
NaPi, 2mM KPi pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM DTT). The following proteins 
were purchased as follows; Clusterin (Enzo Life Sciences, 201-335-C050, Farmingdale, 
NY), PDI (PROSPEC, enz-262-b, East Burnswick, NJ), FKBP12 (PROSPEC, enz-347-c). 
MycF was a kind gift from Janet Smith (University of Michigan); nanobody80 was a kind 




3.5.2 Peptide Microarrays 
A peptide microarray consisting of a variety of peptides experimentally evaluated for their ability 
to form fibrils was designed (Appendix A.1). Empty spots and process controls were used as 
negative controls. The microarrays were printed on single microscope slides in triplicate with 
peptides covalently immobilized at the N-terminus (Jenrin Peptide Technologies, Berlin, 
Germany). Binding was tested per manufacturer’s protocol using 10 µM of His6x-tagged protein 
in binding buffer (25 mM HEPES pH 7.2, 150 mM NaCl, 20 mM KCl, 5 mM MgCl2, 0.01% 
Tween20).  Binding was detected using 1:1,000 titer of HiLyte555 anti-His6x antibody 
(Anaspec, Fremont, CA) in TBS-T with 1% bovine serum albumin (Sigma) and scanning the 
microarrays using a GenePix 4100A Microarray Scanner (Molecular Devices, Sunnyvale, CA) 
and an excitation wavelength of 532 nm. Binding was defined using a previously described 
peptide microarray analysis program, Rapmad, to identify bound peptides while excluding false 
positives identified in the Hsp70 NBD experiment [138].  The optional random forest procedure 
to remove potentially unreliable peptide spots was excluded from the analysis. Odds ratios (OR) 
were calculated for each individual experiment using the following equation;  
           OR = (FB*NN)/(NB*FN)   (Equation 1) 
FB indicates fibril forming peptides found to bind the chaperone, FN indicates fibril forming 
peptides found to not bind, NB indicates non-fibril forming peptides found to bind, and NN 
indicates non-fibril forming peptides found to not bind. Further, for proteins tested more than 
once, an OR was calculated for the combined data. In combining the data binding was defined as 





























































































































































Appendix 3.2 Tau Array Peptides 
PNS 4R2N Peptide Sequence 
1 1 MAEPRQEFEVMEDHA 
5 5 RQEFEVMEDHAGTYG 
9 9 EVMEDHAGTYGLGDR 
13 13 DHAGTYGLGDRKDQG 
17 17 TYGLGDRKDQGGYTM 
21 21 GDRKDQGGYTMHQDQ 
25 25 DQGGYTMHQDQEGDT 
29 29 YTMHQDQEGDTDAGL 
33 33 QDQEGDTDAGLKESP 
37 37 GDTDAGLKESPLQTP 
41 41 AGLKESPLQTPTEDG 
45 45 ESPLQTPTEDGSEEP 
49 49 QTPTEDGSEEPGSET 
53 53 EDGSEEPGSETSDAK 
57 57 EEPGSETSDAKSTPT 
61 61 SETSDAKSTPTAEDV 
65 65 DAKSTPTAEDVTAPL 
69 69 TPTAEDVTAPLVDEG 
73 73 EDVTAPLVDEGAPGK 
77 77 APLVDEGAPGKQAAA 
81 81 DEGAPGKQAAAQPHT 
85 85 PGKQAAAQPHTEIPE 
89 89 AAAQPHTEIPEGTTA 
93 93 PHTEIPEGTTAEEAG 
97 97 IPEGTTAEEAGIGDT 
101 101 TTAEEAGIGDTPSLE 
105 105 EAGIGDTPSLEDEAA 
109 109 GDTPSLEDEAAGHVT 
113 113 SLEDEAAGHVTQEPE 
117 117 EAAGHVTQEPESGKV 
121  HVTQEPESGKVVQEG 
125  EPESGKVVQEGFLRE 
129  GKVVQEGFLREPGPP 
133  QEGFLREPGPPGLSH 
137  LREPGPPGLSHQLMS 
141  GPPGLSHQLMSGMPG 
145  LSHQLMSGMPGAPLL 
149  LMSGMPGAPLLPEGP 
153  MPGAPLLPEGPREAT 
157  PLLPEGPREATRQPS 
161  EGPREATRQPSGTGP 
165  EATRQPSGTGPEDTE 
169  QPSGTGPEDTEGGRH 
173  TGPEDTEGGRHAPEL 
177  DTEGGRHAPELLKHQ 
181  GRHAPELLKHQLLGD 
185  PELLKHQLLGDLHQE 
189  KHQLLGDLHQEGPPL 
193  LGDLHQEGPPLKGAG 
197  HQEGPPLKGAGGKER 
201  PPLKGAGGKERPGSK 
205  GAGGKERPGSKEEVD 
209  KERPGSKEEVDEDRD 
213  GSKEEVDEDRDVDES 
217  EVDEDRDVDESSPQD 
221  DRDVDESSPQDSPPS 
225  DESSPQDSPPSKASP 
229  PQDSPPSKASPAQDG 
233  PPSKASPAQDGRPPQ 
237  ASPAQDGRPPQTAAR 
241  QDGRPPQTAAREATS 
245  PPQTAAREATSIPGF 
249  AAREATSIPGFPAEG 
253  ATSIPGFPAEGAIPL 
257  PGFPAEGAIPLPVDF 
261  AEGAIPLPVDFLSKV 
265  IPLPVDFLSKVSTEI 
269  VDFLSKVSTEIPASE 
273  SKVSTEIPASEPDGP 
277  TEIPASEPDGPSVGR 
281  ASEPDGPSVGRAKGQ 
285  DGPSVGRAKGQDAPL 
289  VGRAKGQDAPLEFTF 
293  KGQDAPLEFTFHVEI 
297  APLEFTFHVEITPNV 
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301  FTFHVEITPNVQKEQ 
305  VEITPNVQKEQAHSE 
309  PNVQKEQAHSEEHLG 
313  KEQAHSEEHLGRAAF 
317  HSEEHLGRAAFPGAP 
321  HLGRAAFPGAPGEGP 
325  AAFPGAPGEGPEARG 
329  GAPGEGPEARGPSLG 
333  EGPEARGPSLGEDTK 
337  ARGPSLGEDTKEADL 
341  SLGEDTKEADLPEPS 
345  DTKEADLPEPSEKQP 
349  ADLPEPSEKQPAAAP 
353  EPSEKQPAAAPRGKP 
357  KQPAAAPRGKPVSRV 
361  AAPRGKPVSRVPQLK 
365  GKPVSRVPQLKARMV 
369  SRVPQLKARMVSKSK 
373 125 QLKARMVSKSKDGTG 
377 126 RMVSKSKDGTGSDDK 
381 130 KSKDGTGSDDKKAKT 
385 134 GTGSDDKKAKTSTRS 
389  DDKKAKTSTRSSAKT 
393  AKTSTRSSAKTLKNR 
397  TRSSAKTLKNRPCLS 
401  AKTLKNRPCLSPKLP 
405  KNRPCLSPKLPTPGS 
409  CLSPKLPTPGSSDPL 
413  KLPTPGSSDPLIQPS 
417  PGSSDPLIQPSSPAV 
421  DPLIQPSSPAVCPEP 
425  QPSSPAVCPEPPSSP 
429  PAVCPEPPSSPKHVS 
433  PEPPSSPKHVSSVTS 
437  SSPKHVSSVTSRTGS 
441  HVSSVTSRTGSSGAK 
445  VTSRTGSSGAKEMKL 
449  TGSSGAKEMKLKGAD 
453  GAKEMKLKGADGKTK 
457 143 MKLKGADGKTKIATP 
461 144 GADGKTKIATPRGAA 
465 148 KTKIATPRGAAPPGQ 
469 152 ATPRGAAPPGQKGQA 
473 156 GAAPPGQKGQANATR 
477 160 PGQKGQANATRIPAK 
481 164 GQANATRIPAKTPPA 
485 168 ATRIPAKTPPAPKTP 
489 172 PAKTPPAPKTPPSSG 
493 176 PPAPKTPPSSGEPPK 
497 180 KTPPSSGEPPKSGDR 
501 184 SSGEPPKSGDRSGYS 
505 188 PPKSGDRSGYSSPGS 
509 192 GDRSGYSSPGSPGTP 
513 196 GYSSPGSPGTPGSRS 
517 200 PGSPGTPGSRSRTPS 
521 204 GTPGSRSRTPSLPTP 
525 208 SRSRTPSLPTPPTRE 
529 212 TPSLPTPPTREPKKV 
533 216 PTPPTREPKKVAVVR 
537 220 TREPKKVAVVRTPPK 
541 224 KKVAVVRTPPKSPSS 
545 228 VVRTPPKSPSSAKSR 
549 232 PPKSPSSAKSRLQTA 
553 236 PSSAKSRLQTAPVPM 
557 240 KSRLQTAPVPMPDLK 
561 244 QTAPVPMPDLKNVKS 
565 248 VPMPDLKNVKSKIGS 
569 252 DLKNVKSKIGSTENL 
573 256 VKSKIGSTENLKHQP 
577 260 IGSTENLKHQPGGGK 
581 264 ENLKHQPGGGKVQII 
585 268 HQPGGGKVQIINKKL 
589 272 GGKVQIINKKLDLSN 
593 276 QIINKKLDLSNVQSK 
597 280 KKLDLSNVQSKCGSK 
601 284 LSNVQSKCGSKDNIK 
605 288 QSKCGSKDNIKHVPG 
609 292 GSKDNIKHVPGGGSV 
613 296 NIKHVPGGGSVQIVY 
617 300 VPGGGSVQIVYKPVD 
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621 304 GSVQIVYKPVDLSKV 
625 308 IVYKPVDLSKVTSKC 
629 312 PVDLSKVTSKCGSLG 
633 316 SKVTSKCGSLGNIHH 
637 320 SKCGSLGNIHHKPGG 
641 324 SLGNIHHKPGGGQVE 
645 328 IHHKPGGGQVEVKSE 
649 332 PGGGQVEVKSEKLDF 
653 336 QVEVKSEKLDFKDRV 
657 340 KSEKLDFKDRVQSKI 
661 344 LDFKDRVQSKIGSLD 
665 348 DRVQSKIGSLDNITH 
669 352 SKIGSLDNITHVPGG 
673 356 SLDNITHVPGGGNKK 
677 360 ITHVPGGGNKKIETH 
681 364 PGGGNKKIETHKLTF 
685 368 NKKIETHKLTFRENA 
689 372 ETHKLTFRENAKAKT 
693 376 LTFRENAKAKTDHGA 
697 380 ENAKAKTDHGAEIVY 
701 384 AKTDHGAEIVYKSPV 
705 388 HGAEIVYKSPVVSGD 
709 392 IVYKSPVVSGDTSPR 
713 396 SPVVSGDTSPRHLSN 
717 400 SGDTSPRHLSNVSST 
721 404 SPRHLSNVSSTGSID 
725 408 LSNVSSTGSIDMVDS 
729 412 SSTGSIDMVDSPQLA 
733 416 SIDMVDSPQLATLAD 
737 420 VDSPQLATLADEVSA 
741 424 QLATLADEVSASLAK 
744 427 TLADEVSASLAKQGL 
P1 P1 GYSSPGEPGEPGSRS 
P2 P2 GYSSPGEPGTPGSRS 
P3 P3 PGSPGEPGSRSRTPS 
P4 P4 VKSKIGETENLKHQP 
P5 P5 DRVQSKIGELDNITH 
P6 P6 HGAEIVYKEPVVSGD 
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Characterizing the Interaction of Hsc70 with Amyloidogenic Substrates 
 
4.1 Abstract 
A number of untreatable neurodegenerative diseases, including Alzheimer’s and 
Huntington’s diseases, are characterized by the deposition of amyloid fibrils. Amyloids are 
formed by the aggregation of misfolded proteins. Several molecular chaperones are able to 
prevent amyloid formation, both in vivo and in vitro. To better understand how chaperones 
interact with amyloids, we developed a peptide microarray consisting of ~60 fibril-forming 
peptides and ~60 sequences that are unable to form amyloids. These sequences were 
matched for their hydrophobicity, length and number of aromatic residues to focus the study 
on whether chaperones might be able discriminate between normal and amyloid-forming 
peptides. We then measured binding of 20 different chaperones to these arrays, which 
suggested that Hsp70s, Hsp90, and some J proteins have a slight preference for amyloid-
forming sequences. We selected 10 peptides from this dataset and investigated their binding 
to the substrate-binding domain (SBD) of Hsc70 using fluorescence polarization (FP) and 
isothermal titration calorimetry (ITC). We confirmed some of the Hsc70-peptide 
interactions and also identified a number of false negatives and positives. Together, these 
results suggest that some amyloid-prone sequences are good Hsc70 “clients’, but that other 




4.2.1 Amyloid fibers share a common structure 
At least 25 diseases are characterized by the assembly of misfolded proteins into rigid 
amyloid fibrils. The proteins that form these amyloids, such as tau (see Chapter 3), 
huntingtin and amyloid-β (Aβ), are diverse in sequence but they all form fibrils that are rich 
in β-sheet content and have similar dimensions [1, 2]. Further, all amyloids bind tightly to 
histological stains, such as Congo Red and Thioflavin T. Recent structural studies have 
revealed that amyloid cores contain “dry steric zippers”. These structures are characterized 
by the tight interdigitation of amino acid side chains and the exclusion of water [3]. For 
example, the hexapeptide sequences VQIINK and VQIVYK at the core of tau amyloids 
align in anti-parallel β-sheets, with the side chains tightly packed [4]. The Eisenberg 
laboratory has solved the structures of thousands of steric zippers and developed an 
algorithm, ZipperDB, that is able to predict amyloid propensity in sequences [5]. The 
identification of these sequences provides a new focus for therapeutic approaches.  
 
4.2.2 Chaperones prevent amyloid formation and protect against disease 
In vitro, Hsp70, J proteins and other chaperones potently suppress the formation of many 
amyloids, including those formed from tau (see Chapter 3), amyloid-β (Alzheimer’s 
disease), α-synuclein (Parkinson’s disease), polyQ-expanded huntingtin (Huntington’s 
disease), amylin (type 2 diabetes) and insulin (injection amyloidosis) [6] [7-15]. Hsp70 
appears to block amyloid formation by directly binding to the amyloidogenic protein and 
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blocking its aggregation This activity is sometimes dependent on ATPase activity but some J 
proteins also inhibit aggregation in the absence of enzymatic activity  
 
One fascinating aspects of these previous findings is that individual chaperones, such as 
Hsp70, are able to prevent amyloid formation by peptides that are widely divergent in 
sequence and physicochemical properties. For example, Hsp70 is a potent suppressor of 
amyloid formation by highly polar polyglutamine sequences and largely hydrophobic 
KLVFF-based amyloids [7, 8]. These types of observations suggest that Hsp70 can identify 
both of these “dangerous” sequences even though they share no similar physicochemical 
characteristics. What these sequences share in common is the ability to form steric zippers. 
Thus, we wondered whether chaperones, especially Hsp70 and J proteins, might be able to 
discriminate between innocuous and “dangerous” sequences. We also wanted to explore 
whether all chaperones share this ability or whether some chaperones were more “attuned” 
to finding amyloids. Moreover, we wondered whether these chaperones might bury the 
amyloid sequences into their substrate-binding domains (SBDs) to prevent the recruitment 
of additional monomers. An understanding of this mechanism may provide insight into 
how chaperones normally protect against amyloid formation and toxicity. 
4.3 Results 
4.3.1 Amyloid peptide microarray 
To study chaperone binding to amyloid-prone sequences, Dr. Andrea Thompson and Dr. 
Atta Ahmad designed a peptide microarray consisting of 120 peptides derived from 33 




Table 4.1 Odds ratio analysis of chaperones binding fibril-forming peptides 
 
Sample type Human Chaperone Replicates Odds Ratio 95% CI 
Negative control Hsp70 NBD 4 0.942 0.308-2.882 
Hsp70/Hsp90 Hsc70 (HSPA8) 4 2.063 0.920-4.625 
  Hsc70SBD 1 1.884 0.767-4.627 
  DnaK (E. coli) 1 1.803 0.767-4.235 
  Hsp70 (HSPA1B) 1 1.722 0.783-3.789 
  Hsp90 (HSP90AA1) 2 2.150 0.737-6.271 
Small Hsps Hsp27 (HSPB1) 1 1.488 0.615-3.600 
  Hsp22 (HSPB8) 2 0.939 0.180-0.489 
  ab crystallin (HSPB5) 2 0.887 0.304-2.586 
Negative control J-domain DnaJ (E.coli) 2 1.472 0.392-5.519 
Co-chaperones DNAJA2 4 2.343 1.025-5.356 
  DnaJ (E.coli) 1 2.844 1.145-7.066 
  DNAJA1 1 2.418 0.893-6.541 
  DNAJB1 2 2.263 0.871-5.877 
  CHIP 2 2.090 0.661-6.606 
  FKBP51 (FKBP5) 3 1.720 0.754-3.974 
  DNAJB4 1 0.519  0.083-3.246 
  Hop 1 no binding   
Other chaperones FKBP12 2 no binding   
  PDI 1 0.404 0.095-1.712 
  clusterin 1 1.026 0.473-6.079 
Ub-conj enzymes Ube2w 1 1.667 0.376-7.385 
  UbcH5c 1 0.576 0.130-2.544 
More negative 
controls MycF 1 1.804 0.316-10.314 
  nano80 1 1.044 0.348-3.126 
  Antibody alone 3 0.461 0.040-5.250 
Odds ratios (OR) and 95% confidence intervals were calculated based on binding data 
from chaperones on the amyloid peptide microarrays. An odds ratio greater than one 
indicates a preference for binding fibril-forming peptides over non-fibril forming. Dark 
grey indicates chaperones that exhibited a preference for fibril-forming peptides. Light 
grey indicates chaperones that had an OR > 1.5 but did not reach significance using a 
95% CI. Some chaperones (e.g. Ube2w) had a reasonably high OR but due to binding 
very few peptides had a broad 95% CI and were thus not considered to represent a real 
preference. 
 
forming) and ~60 non-amyloidogenic peptides. The pools of peptides were matched for 
their physicochemical properties, including their hydrophobicity, number of aromatic 
residues, length, molecular mass and overall charge (Appendix 4.2). The amyloid-forming 
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sequences were chosen from the literature, especially the structural studies of the Eisenberg 
group and, when possible, the non-amyloid forming peptides were chosen from non-
amyloid forming sequences in the same proteins. Chaperone binding to this array was 
detected using the same procedure outlined in Chapter 3. 
 
4.3.2 A subset of chaperones preferentially bind amyloidogenic peptides 
We tested binding of chaperones from a range of structural classes, including Hsp70s, 
Hsp90s, J proteins, other co-chaperones, small heat shock proteins and components of the 
ubiquitin-proteasome system. For each chaperone, we calculated an odds ratio (OR) and 
used a 95% confidence interval to determine whether it could discriminate between amyloid 
and non-amyloid peptides (OR > 1.0 indicates a preference for binding fibril-forming 
peptides; see Section 4.5 for details). By this analysis, two co-chaperones – DNAJA2 and E. 
coli DnaJ – bound preferentially to amyloid-forming sequences. However, the relatively 
small size of the dataset limited its statistical power, so many chaperones, including 
Hsc70/Hsp72, DnaK, Hsp90, DNAJA1, DNAJB1, CHIP and FKBP51, had OR values 
consistently above 1 but they failed to reach significance. Other chaperones, particularly the 
small heat shock proteins and E2 ubiquitin-conjugating enzymes, did not show any 
preference for fibril forming peptides. 
 
It is worth emphasizing that even the chaperones with a tendency to bind amyloid-forming 
sequences also bound other peptides. This result is not surprising given the known 
promiscuity of Hsp70 and other chaperones. In fact, it is quite remarkable that any 
chaperones showed a preference in this format, given the wide range of activities that 
 
 131 
chaperones such as Hsp70 carry out. Thus, these data suggest that some chaperones are able 
to directly identify amyloid-prone sequences and that some chaperones are even able to 
differentiate these sequences from other, chemically similar sequences. However, no 
chaperone appeared able to bind all amyloids.  
 
4.3.3 Hsc70SBD binding of peptides using fluorescence polarization 
To further explore the amyloid-chaperone interactions, we divided the sequences into four 
categories: fibril-forming binders, fibril forming non-binders, non-fibril forming binders and 
non-fibril forming non-binders. “Binders” were characterized as peptides bound by 
DNAJA1, DNAJA2, DNAJB1, Hsc70/Hsc70SBD, Hsp72 and Hsp90 (at least 5 of these 6). 
The raw binding results were also examined to ensure that the peptides chosen for further 
study were robust and from disease-associated proteins (Table 4.2).  
 
Table 4.2 Peptides selected for binding studies 
Category Peptide Parent Protein 
FP  
IC50 (µM)a Reference 
Fibril-forming LVEALY Insulin 43 ± 9 [4, 16, 17] 
Binders SLYQLENY Insulin 7 ± 2 [18] 
  VQIVYK Tau 33 ± 10 [4, 19] 
Non-fibril-forming EALYLV b2-microglobulin 8 ± 3 [16, 17] 
Binders GERGFF Insulin > 200 [16, 17] 
Fibril-forming KLVFFAED Amyloid-b > 200 [20, 21] 
Non-binders GSIAAT a-synuclein 39 ± 9 [4] 
Non-fibril-forming KSNFLN b2-microglobulin 32 ± 4 [16, 17] 
Non-binders VQPVYK Tau (mutant) > 200 [19] 
  HLVEAL Insulin 140 ± 70 [16, 17] 
aIC50 values of peptides competing with 5Fam-labeled LVEALY (20 nM) 




The microarray study is only semi-quantitative and binding is measured at a liquid-solid 
interface. To study these interactions in solution by a distinct platform, we developed a 
fluorescence polarization (FP) assay. For these studies, we focused on Hsc70SBD and 
employed the known fluorescent tracer, LVEALY [17] (Figure 4.1). We found that the 
peptide bound with comparable affinity (~1 µM) to two different Hsc70SBD constructs, 394-
540 and 394-509, the latter of which has the helical “lid” domain removed. The smaller 
construct was designed for NMR structural studies. Because both proteins yielded similar 
affinity for the tracer, we conducted the remainder of our studies with the 394-540 construct. 
Unfortunately, we were unable to detect binding of this tracer to any of the J proteins.. 
 
The ability of the peptides to compete with 20 nM 5Fam-LVEALY for binding to Hsc70SBD 
was evaluated (Figure 4.2) and IC50 values estimated (Table 4.2). As expected, unlabeled 
LVEALY competed with the labeled tracer, with the disparity between the affinity of the 
tracer (1.7 µM) and the IC50 value of the unlabeled peptide (42 µM) likely attributable to 
affinity contributed by the fluorophore. The 
other two fibril-forming binders 
(SLYQLENY and VQIVYK) also competed 
with the tracer, with SLYQLENY having 
an appreciably lower IC50 than LVEALY. 
Of the two non-fibril-forming binders, one 
competed well (EALYLV) and the other 
(GERGFF) did not. The result with 




was either a false positive or that the chaperone recognized some feature of the immobilized 
peptide that was not replicated in the solution FP format (e.g. solubility, secondary 
structure, local concentration, etc). Similarly, one fibril-forming non-binder competed well 
(GSIAAT) and the other did not (KLVFFAED). Finally, one non-fibril forming non-binder 
competed well (KSNFLN) while the others did not (HLVEAL and VQPVYK). Although 
the sample size of this dataset is small, these results suggest that the arrays predicted ~70% 
of the chaperone interactions with Hsc70.. 
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LVEALY, EALYLV, and HLVEAL were selected for further study in part because they 
have similar sequences yet disparate fibril-forming properties and behavior on the arrays. 
LVEALY and EALYLV are highly similar, but EALYLV doesn’t form amyloids. 
Nevertheless, Hsc70SBD bound the two peptides with similar affinity, confirming previous 
suggestions that physicochemical characteristics play a major role in Hsp70 binding [22]. 
However, a one-residue shift from LVEALY to HLVEAL nearly abolished binding by 
Hsc70SBD in both the microarray and FP platforms. This result is in contrast to the known 
preference of Hsp70 for binding positively charged residues flanking a hydrophobic core 
[22]. This result suggests that the Phe residue at the end of LVEALY may be important for 
interaction with Hsc70 and may allow the chaperone to identify this “dangerous” sequence. 
 
As discussed in Chapter 3, the tau sequence, VQIVYK (aka PHF6), is required for forming 
PHFs and this hexapeptide forms fibrils consisting of steric zippers [4]. VQPVYK is a 
closely related peptide that contains a point mutation (Ile to Pro) known to abolish amyloid 
formation [19]. Interestingly, this point mutant also abolished Hsc70 binding in our FP and 
microarray experiments. This finding could be due to a requirement for the Ile side chain in 
the binding interaction or a loss of β-sheet propensity altering the conformational dynamics 
of the peptide. 
 
Together these data provide evidence that Hsc70 has a mild, global preference for fibril-
forming peptides over non-fibril forming and that this preference is particularly strong for 




4.3.4 Characterizing Hsc70SBD-peptide binding by isothermal titration calorimetry 
Next, we measured binding of the peptides to Hsc70SBD by ITC. We pursued these studies 
because the FP assay was designed to measure competition between the peptides and the 
fluorescent tracer, so we also wanted to test whether the peptides might bind a distinct site 
on the SBD. Briefly, a solution of peptide (400 µM) was injected into a buffer-matched 
solution of Hsc70SBD (30 µM) and the thermodynamic binding parameters determined using 
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MicroCal software (Figure 4.3 and Appendix 4.3). Some of these studies required addition 
of up to 4% DMSO to both the protein and peptide samples, a process which resulted in 
buffer mismatch issues and thus the high background observed in some titrations. 
 
 
Of the ten peptides, one was not soluble enough to yield accurate measurements and these 
results were discarded (Table 4.3). Of the remaining peptides, each bound to Hsc70SBD with 
varying affinity (∆G values between -7 and -8.5 kcal mol-1). The binding of all peptides was 
enthalpically and entropically favorable. The low n-values (0.4-0.9 peptides/Hsc70SBD) are 
likely due to the Hsc70SBD binding pocket being partially occupied by co-purified 
peptides/proteins. However, the variation among the n-values suggests that the peptide 
concentrations may be imprecise; future experiments should employ techniques to precisely 
determine peptide concentration in solution, such as amino acid analysis, in order to obtain 
completely accurate affinities and n-values. For this reason, we consider these data to be 
simply indications of binding or non-binding, while future studies will determine relative 
affinities. 









(cal mol-1 K-1) 
∆G b  
(kcal mol-1) n 
LVEALY 2.05 x 105 ± 6.8 x 104 6 ± 2 -746 ± 137 22 -7.18 0.7 
SLYQLENY 2.78 x 105 ± 4.7 x 104 3.6 ± 0.6 -4548 ± 282 9.6 -7.42 0.5 
VQIVYK 1.53 x 106 ± 2.1 x 105 0.65 ± 0.09 -1008 ± 16 24.9 -8.43 0.8 
EALYLV 4.29 x 105  ± 5.0 x 104 2.3 ± 0.3 -2263 ± 108 18.2 -7.69 0.4 
GERGFF 5.04 x 105  ± 4.5 x 104 2.0 ± 0.2 -1450 ± 22 21.2 -7.77 0.9 
KLVFFAED insoluble 
     GSIAAT 5.1 x 105  ± 1.5 x 105 2.0 ± 0.6 -319 ± 25 25 -7.77 0.5 
KSNFLN 5.66 x 105  ± 1.4 x 105 1.8 ± 0.5 -1218 ± 63 22.2 -7.83 0.6 
VQPVYK 6.87 x 105  ± 1.2 x 105 1.5 ± 0.3 -351 ± 11 25.5 -7.95 0.8 
HLVEAL no binding 
     
aValues are for 25 mM HEPES, 5 mM MgCl2, 10 mM KCl, 0-4% DMSO, pH 7.4, 25 oC 
b∆G = ∆H - T∆S 
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Comparing these results to the FP assay findings, it appeared that more peptides were 
positive binders. For example, both GERGFF and VQPVYK bound Hsc70, yet these 
peptides failed to compete with the LVEALY tracer. Thus, these peptides might have a non-
canonical binding site on the SBD. Consistent with the FP study, HLVEAL did not bind 
strongly to Hsc70SBD.  
 
4.4 Discussion 
We have used a peptide microarray to study binding of chaperones to fibril-forming 
peptides. This study is important because many chaperones, especially Hsp70 and small 
heat shock proteins, and co-chaperones, such as J proteins, have been strongly linked to 
preventing amyloid formation and toxicity. The previous studies had suggested that some 
chaperones might be able to identify the regions of amyloid-prone proteins critical for 
amyloid formation, yet there was little structural or biophysical evidence for such as model. 
Accordingly, we used peptide microarrays, FP and ITC to investigate these interactions, 
with a special focus on Hsc70. The array studies suggested a mild preference of a subset of 
the chaperones. This result is surprising and interesting because it suggests that some 
chaperones might be able to find “dangerous” sequences independent of their other 
commonly evaluated physicochemical properties. With FP, we evaluated the ability of a set 
of 10 peptides to compete with a fluorescent LVEALY tracer for binding to Hsc70SBD. This 
assay yielded a 70% confirmation rate, with both false positives and negatives identified. 
Because of these false positives and negatives, the odds ratios originally calculated from the 
microarray data may not fully reflect the binding preferences of chaperones. Further, these 
results suggest that the peptides may be forming structures on the array surface that are not 
represented in solution, although this model remains to be tested. Finally, using ITC, we 
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elucidated the thermodynamic parameters of Hsc70SBD binding to 8 of these peptides. We 
found that one peptide did not bind and that the others bound with similar affinities. The 
ability of GERGFF and VQPVYK to bind Hsc70 by ITC, but not FP, suggest that these 
peptides do not share a binding site with the LVEALY tracer. To address this possibility, 
studies are underway using NMR to investigate the binding of peptides to Hsc70SBD. Initial 
results with LVEALY suggest that the peptide interacts with disordered loops in the SBD 
and not the β-strands. Further investigations will hopefully clarify the possibility of multiple 
sites. Further, computational and experimental studies are ongoing in collaboration with the 
lab of David Eisenberg to evaluate whether chaperones can form “heterosteric zippers” with 
amyloid sequences.   
 
4.5 Experimental Methods 
4.5.1 Protein purification 
Hsp70s (DnaK, Hsc70, Hsp70, NBD constructs; Hsp70 NBD (1-383), Hsc70 NBD (1-383), 
and Hsc70 NBD+linker (1-394)) were purified as previously described [23]. Likewise, 
Hsp90, J-domain (1-108), and DnaJ were purified as previously described [23, 24], with the 
addition of a Superdex 200 size exclusion column (GE Healthcare, Pittsburg, PA) as the last 
step of the J-domain purification. N-terminal His6x-tagged DNAJA1, DNAJA2, and 
DNAJB1 were purified as previously described [25]. Hsc70SBD (394-540) was expressed in 
BL21 cells from a pMCSG7 vector encoding an N-terminal His6x tag under ampicillin 
selection. Cells were lysed by sonication into His6x-binding buffer (50 mM Tris pH 8.0, 10 
mM imidazole, 500 mM NaCl, protease inhibitors) and purified using Ni-NTA resin 
(Novagen, Darmstadt, Germany). Protein was eluted with His6x-elution buffer (50 mM 
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Tris, 300 mM imidazole, 300 mM NaCl), 2 mM EDTA added, and protein concentrated to 
~6 mg/mL.  Protein was further purified on a HiLoad Superdex 75 16/600 size exclusion 
column into storage buffer (50 mM Tris, 250 mM NaCl). Pure fractions were combined, 
concentrated, flash frozen and stored at -80oC. Hsp27, Hsp22, αB crystallin,  
expressed in Rosetta cells using the pMCSG7 vector. Cells were lysed by sonication into 
lysis buffer (20 mM Tris pH 8.0, 100 mM NaCl, 6 M urea, 5 mM β-mercaptoethanol, 15 
mM imidazole) and purified by standard denaturing his purification using Ni-NTA resin. 
Proteins were eluted with 150 mM imidazole. Following elution EDTA was added to 5 mM 
and protein was concentrated to ~20 mg/ml. Protein was refolded upon injection on a 
Superdex 200 size exclusion column (GE Healthcare, Pittsburg, PA) with refolding buffer 
(20 mM NaPi  pH 7.2, 100 mM NaCl).  The protein was flash frozen and stored at -80 oC. 
Finally, FKBP51 was purified by using a standard His purification with Ni-NTA resin 
(Novagen) followed by separation using a superdex 200 size exclusion column in (10mM 
NaPi, 2mM KPi pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1 mM DTT). The following proteins 
were purchased as follows; Clusterin (Enzo Life Sciences, 201-335-C050, Farmingdale, 
NY), PDI (PROSPEC, enz-262-b, East Burnswick, NJ), FKBP12 (PROSPEC, enz-347-c). 
MycF was a kind gift from Janet Smith (University of Michigan); nanobody80 was a kind 
gift from Roger Sunahara (University of Michigan). 
 
4.5.2 Peptide microarrays 
A peptide microarray consisting of a variety of peptides experimentally evaluated for their ability 
to form fibrils was designed (Appendix A.1). Empty spots and process controls were used as 
negative controls. The microarrays were printed on single microscope slides in triplicate with 
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peptides covalently immobilized at the N-terminus (Jenrin Peptide Technologies, Berlin, 
Germany). Binding was tested per manufacturer’s protocol using 10 µM of His6x-tagged protein 
in binding buffer (25 mM HEPES pH 7.2, 150 mM NaCl, 20 mM KCl, 5 mM MgCl2, 0.01% 
Tween20).  Binding was detected using 1:1,000 titer of HiLyte555 anti-His6x antibody 
(Anaspec, Fremont, CA) in TBS-T with 1% bovine serum albumin (Sigma) and scanning the 
microarrays using a GenePix 4100A Microarray Scanner (Molecular Devices, Sunnyvale, CA) 
and an excitation wavelength of 532 nm. Binding was defined using a previously described 
peptide microarray analysis program, Rapmad, to identify bound peptides while excluding false 
positives identified in the Hsp70 NBD experiment [26].  The optional random forest procedure to 
remove potentially unreliable peptide spots was excluded from the analysis. Odds ratios (OR) 
were calculated for each individual experiment using the following equation;  
           OR = (FB*NN)/(NB*FN)   (Equation 1) 
FB indicates fibril forming peptides found to bind the chaperone, FN indicates fibril forming 
peptides found to not bind, NB indicates non-fibril forming peptides found to bind, and NN 
indicates non-fibril forming peptides found to not bind. Further, for proteins tested more than 
once, an OR was calculated for the combined data. In combining the data binding was defined as 
peptides found to bind in ≥ 2/3 of experiments for that chaperone (see Appendix A.3 for full 
results). 
 
4.5.3 Fluorescence polarization 
Fluorescence polarization experiments were performed in 384-well, black, low volume, 
round-bottom plates (Corning) using a BioTek Synergy 2 plate reader (Winooski, VT). To 
each well was added increasing amounts of protein and the 5-carboxyfluorescein (5-Fam) 
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labeled LVEALY tracer (20 nM) to a final volume of 20 uL in the assay buffer (50 mM 
HEPES, 75 mM NaCl, 0.01% Triton X-100, pH 7.4). The plate was allowed to incubate at 
room temperature for 1 h to reach equilibrium. The polarization values in millipolarization 
units (mP) were measured at an excitation wavelength at 485 nm and an emission 
wavelength at 528 nm. An equilibrium binding isotherm was constructed by plotting the FP 
reading as a function of the protein concentration at a fixed concentration of tracer (20 nM). 
All experimental data were analyzed using Prism 5.0 software (Graphpad Software, San 
Diego, CA) and the inhibition constants (IC50) were determined by nonlinear curve fitting 
to identify the concentration of protein at which 50% of the tracer (ligand) was bound. 
 
4.5.4 Isothermal titration calorimetry 
Hsc70SBD (394-540) was dialyzed extensively into Buffer A (25 mM HEPES, 5 mM 
MgCl2, 10 mM KCl, pH 7.4) and buffer from the dialysis was saved for concentration 
adjustment. Peptide (400 µM) and Hsc70SBD (30 µM) solutions were made fresh with 0-4% 
DMSO (as required for peptide solubility) and degassed for 10-20 minutes. Peptide was 
titrated into Hsc70SBD (5 µL injections, stirring 310 RPM, 25-35 injections) at 25 oC. 
Experiments were carried out on a VP-ITC instrument (MicroCal, Northampton, MA) and 
data was analyzed using the Origin 7 software package. All binding isotherms were fit using 
the single set of identical sites model. 
 
Notes  
Andrea Thompson and Atta Ahmad designed the amyloid peptide microarray. Andrea 
Thompson, Amanda Wong, and Anne Gillies carried out the microarray experiments and 
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data analysis. Victoria Assimon carried out the FP experiments and data analysis. Anne 
Gillies carried out the ITC experiments and data analysis. Andrea Thompson, Anne Gillies, 
Victoria Assimon, and Jason Gestwicki contributed intellectually to this work. 
 
4.6 Appendix 
Appendix 4.1 Peptide microarray design  
ID # Name Protein   Fibril/Non-Fibril Location 
1 GGVLVN 248PAP286 Fibril [27] cytoplasm 
2 SLFLIG AIM1 non-Fibril [28] membrane 
3 VGGAVVTGV α synuclein Fibril [4, 20] cytoplasm 
4 GSIAAT α synuclein Fibril [4] cytoplasm 
5 GVATVA α synuclein Fibril [4] cytoplasm 
6 GGAVVT α synuclein predicted Fibril [16] cytoplasm 
7 AEKTKQ α synuclein predicted non-fibril [16] cytoplasm 
8 MPVDPD α synuclein predicted non-fibril [16] cytoplasm 
9 NFGAIL amylin Fibril [16, 20, 29, 30]  secreted/extra 
10 FLVHSS amylin Fibril [16, 31]  secreted/extra 
11 TNVGSNTY amylin Fibril [32]  secreted/extra 
12 QRLANFLVH amylin Fibril [33] secreted/extra 
13 SSTNVG amylin Fibril [4] secreted/extra 
14 LIAGFN amylin non-Fibril [16] secreted/extra 
15 NLGPVL amylin non-Fibril [16] secreted/extra 
16 KLVFFAED Aβ Fibril [20, 21] extra 
17 AIIGLMVGGVV Aβ Fibril [4] extra 
18 GGVVIA Aβ Fibril [4] extra 
19 MVGGVV Aβ Fibril [4] extra 
20 DGVVIA Aβ non-fibril FL [34] extra 
21 LVGGVV Aβ non-fibril FL [34, 35]  extra 
22 GFVVIA Aβ non-fibril FL [35] extra 
23 FFKRAA AR predicted non-fibril [16] cytoplasm, nucleus  
24 AVFIIY ASPM Fibril [28] nucleus, cytoplasm 
25 GRGHGG ataxin-1 (ATXN1) predicted non-fibril [16] cytoplasm  
26 DWSFYLLYYTEFT b2-microglobulin Fibril [4, 36] secreted/extra 
27 KDWSFY b2-microglobulin Fibril [17]  secreted/extra 
28 KIVKWD b2-microglobulin Fibril [17] secreted/extra 
29 FYLLYY b2-microglobulin Fibril [17] secreted/extra 
30 LLYYTE b2-microglobulin Fibril [17] secreted/extra 
31 NHVTLS b2-microglobulin Fibril [4, 16, 17, 37] secreted/extra 
32 FHPSDIEVDLLK b2-microglobulin non-Fibril [36] secreted/extra 
33 IQRTPKIQVYSRHPAE b2-microglobulin non-Fibril [36] secreted/extra 
34 LSQPKIVKWDRDM b2-microglobulin non-Fibril [36] secreted/extra 
35 
NGERIEKVEHSDLSFS
KD b2-microglobulin non-Fibril [36] secreted/extra 
36 NGKSNFLNCYVSG b2-microglobulin non-Fibril [36] secreted/extra 
37 PTGKDEYACRVNHVT b2-microglobulin non-Fibril [36] secreted/extra 
38 YVSGFH b2-microglobulin non-Fibril [16, 17] secreted/extra 
39 VYSRHP b2-microglobulin non-Fibril [16, 17] secreted/extra 
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40 KSNFLN b2-microglobulin non-Fibril [16, 17] secreted/extra 
41 RTPKIQ b2-microglobulin non-Fibril [16, 17] secreted/extra 
42 VTLSQP b2-microglobulin non-Fibril [16, 17] secreted/extra 
43 TEFTPT b2-microglobulin non-Fibril [16, 17] secreted/extra 
44 SRHPAE b2-microglobulin non-Fibril [16, 17] secreted/extra 
45 
GGSGGSGGGSDYKD
DDDK   process control  
46 EALYLV b2-microglobulin non-Fibril [16, 17] secreted/extra 
47 DFNKFH Calcitonin Fibril [4, 38] secreted 
 
 
    
     
ID # Name Protein Fibril/Non-Fibril Location 
48 NFVNYS CELR3 Fibril [28] membrane 
49 VTFTIQ CPNE5 Fibril [28] 
cytoplasm, 
membrane 
50 YLVNFT ECM1 Fibril [28] extra membrane 
51 NEFIIT EMBP non-Fibril [28] 
secreted; cytoplasmic 
vesicles 
52 YLVLIM Fibulin-1 non-Fibril [28] secreted/extra 
53 MIFFIY GCYB2 non-Fibril [28] cytoplasm 
54 SAILTA gelsolin (GSN) predicted Fibril [16] 
cytoplasm, 
extracellular  
55 TMSVSL gelsolin (GSN) predicted Fibril [16] 
cytoplasm, 
extracellular  
56 LYNYRH gelsolin (GSN) predicted non-fibril [16] 
cytoplasm, 
extracellular  
57 IRDNER gelsolin (GSN) predicted non-fibril [16] 
cytoplasm, 
extracellular  
58 LYVLIV GRP21 Fibril [28] membrane 
59 QQSLFQ HNRPD Fibril [28] Nucleus, cytoplasm 




AR Fibril [4] cytoplasm 
62 SLYQLENY Insulin Fibril [18] extracellular 
63 LVEALYLV Insulin Fibril [18] extracellular 
64 LVEALY Insulin Fibril [4, 16, 17] extracellular 
65 VEALYL Insulin Fibril [4, 16, 17] extracellular 
66 LYQLEN Insulin Fibril [4, 16, 17] extracellular 
67 YQLENY Insulin Non-Fibril [16, 17] extracellular 
68 FVNQHL Insulin Non-Fibril [16, 17]  extracellular 
69 GSHLVE Insulin Non-Fibril [16, 17]  extracellular 
70 HLVEAL Insulin Non-Fibril [16, 17]  extracellular 
71 FYTPKT Insulin Non-Fibril [16, 17]  extracellular 
72 GERGFF Insulin Non-Fibril [16, 17]  extracellular 
73 GVWWFF Integrin beta-1 Fibril [28] membrane 
74 GIFNIK LASS2 Fibril [28] membrane 
75 IFQINS Lysozyme  Fibril [4, 20] cytoplasm 
76 TFQINS Lysozyme-Hu Fibril [4] cytoplasm 
77 NRLLLTG model substrate Unknown NA 
78 AGAAAAGA Prion Fibril [39, 40] extra membrane 
79 SNQNNF Prion  Fibril [4] extra membrane 
80 VHDCVNITIK Prion 180-193 Fibril [20, 41] extra membrane 
81 NITIKQHTVT Prion 180-193 Non-Fibril  [20, 41] extra membrane 
82 QHTVTTTKG Prion 180-193 Non-Fibril  [20, 41] extra membrane 
83 TTTKGENFTE Prion 180-193 Non-Fibril  [20, 41] extra membrane 
84 MIHFGND Prion(Mu) Fibril [4] extra membrane 
85 SMVLFSSPPV Prion141-150 Fibril  [20, 41] extra membrane 
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86 EDRYYRENMH Prion144-154 non-Fibril  [20, 41] extra membrane 
87 FGSDYEDRYY Prion144-154 non-Fibril  [20, 41] extra membrane 
88 SSEITT PTMA predicted Fibril [16] cytoplasm 
89 EVDEEE PTMA predicted non-fibril [16]  cytoplasm 
90 AA  process control  
91 KRAAED PTMA predicted non-fibril [16]  cytoplasm 
92 SSTSAASSSNY Rnase Fibril [5] cytoplasm 
93 KHIIVA Rnase Fibril [5] cytoplasm 
94 SYSTMS Rnase Fibril [5] cytoplasm 
95 SSTSAA Rnase Fibril [4] Cytoplasm 
ID # Name Protein Fibril/Non-Fibril Location 
96 ASSSNY Rnase  Fibril [5] cytoplasm 
97 RNLTKD Rnase  Non-Fibril [5] cytoplasm 
98 IHKAQN 
Rnase, 
scrambled Non-Fibril [5] cytoplasm 
99 ISMTTS 
Rnase, 
scrambled Non-Fibril [5] cytoplasm 
100 FERQHM 
Rnase, 
scrambled Non-Fibril [5] cytoplasm 
101 GNNQQNY Sup35 Fibril [4] Yeast fibril 
102 NNQQNY Sup35 Fibril [4] Yeast fibril 
103 VQIVYK  Tau (PHF6) Fibril [4, 19] cytoplasm 
104 VQIPYK Tau Non-Fibril [19] cytoplasm 
105 VQPVYK Tau Non-Fibril [19] cytoplasm 
106 GQVEVSKE Tau Non-Fibril [20] cytoplasm 
107 VQEVYK Tau unknown cytoplasm 
108 VQYK Tau unknown cytoplasm 
109 VVRTPPKSPSSAKSR Tau unknown cytoplasm 
110 VQIINK Tau  Fibril [42] cytoplasm 
111 VDLSKVTSK Tau  Non-Fibril [20] cytoplasm 
112 PGGGKVQIVYKPV  Tau (K19) Fibril [20] cytoplasm 
113 PGGKVYKPV  Tau (K19d) Non-Fibril [20] cytoplasm 
114 QTAPVPMPD Tau (K19Glu78) Non-Fibril [20] cytoplasm 
115 GISVHI TDP-43 predicted Fibril [16] cytoplasm 
116 GEVLMV TDP-43 predicted Fibril [16] cytoplasm 
117 LRYRNP TDP-43 predicted non-fibril [16] cytoplasm 
118 VFFFIG TRHDE non-Fibril [28] membrane 
119 WTVNYS WDR36 Fibril [28] cytoplasm 
120 FIVNIV XRP2 Fibril [28] membrane 
 
Appendix 4.2 Microarray peptide characteristics 
  Fibril   Non-Fibril   Unknown 
Number of Peptides 59  56  5  
Experimentally validated 54  49  NA  
disease related 39  44  3  
hexamers 43  41  1  
< or > hexamers 16  15  2  
average length peptide 7.22 3.26 6.91 1.58 6.25 0.50 
average MW 822.51 351.41 807.69 196.87 775.53 95.89 
average pI 5.80 1.37 5.83 1.72 5.83 0.61 
average pos charge 0.29 0.56 0.73 1.06 0.25 0.50 
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average neg charge 0.25 0.54 0.45 0.66 0.25 0.50 
average instability index 26.95 42.76 36.36 43.30 21.26 16.23 
average aliphatic index 108.06 68.01 88.49 73.19 16.25 32.50 
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Future Directions: Developing a Deeper Understanding of Chaperone Networks 
 
5.1 Abstract 
In this thesis, I have presented findings that address how chaperones function in networks of 
competing and cooperating elements. Our results highlight the diversity of functions found 
within a single class of co-chaperones, J proteins. We have additionally demonstrated that 
chaperones interact with substrates in different ways to achieve specific outcomes such as 
refolding, stabilization, degradation, or aggregation prevention.  However, there is much yet 
to learn about the details of chaperone networks, particularly as they relate to disease 
pathologies. A more focused evaluation of individual J protein functions may provide useful 
insights into the Hsp70 machinery and its many roles. Additionally, many questions remain 
about how chaperones interact with tau in both healthy brains and tauopathies. Finally, our 
findings suggest that direct binding of amyloidogenic sequences by chaperones may play a 
key role in the prevention of amyloid formation, and a mechanistic understanding of this 
interaction may contribute to our understanding of protein misfolding in disease.  
 
5.2 Conclusions 
Chaperones have emerged as an exciting area of research that touches on many diverse 
aspects of biology. These ubiquitous proteins have long been silent actors in otherwise well-
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understood processes, but their importance in normal cell function is beginning to be 
appreciated. At the same time, the role of chaperones in prevalent and challenging diseases, 
notably neurodegeneration and cancer, as well as their potential as therapeutic targets is 
being recognized. In recent years, our understanding of chaperones has improved by leaps 
and bounds at the mechanistic and systemic levels, but there is still much to be learned.  
 
The goal of this thesis was to study chaperones as a network of interconnected actors. I was 
particularly intrigued by the diversity of J proteins, a co-chaperone class that has been 
dramatically expanded by evolution to support ever more complex organisms. Similarly, 
other classes of chaperones and co-chaperones have multiple members whose unique and 
shared functions are beginning to be elucidated. In order to obtain novel insights into the 
nature of these cooperative networks, I employed two techniques: chemical genetics and 
peptide microarrays. In Chapter 2 I describe the use of chemical genetics to study the effect 
of the loss of a specific J protein on S. cerevisiae. Overall, the deletion of individual 
chaperones had minimal effects on S. cerevisiae viability, suggesting either that the cell has 
compensatory mechanisms in the absence of a single J protein or that the full complement 
of J proteins is unnecessary in ideal growing conditions. However, when the cells were 
challenged with stressors, differences between the J proteins became clearly apparent. Some, 
like Ydj1 and Zuo1, appear to be generalists required for overall cellular health because 
deletion of these genes conferred sensitivity to many different stressors targeting functions 
ranging from cell wall synthesis to TOR signaling. The majority of the J proteins appear to 
have more specialized roles, though the lack of clear-cut functional divisions suggests that 
individual J protein deletion may have a domino effect on multiple pathways. Still others 
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did not confer any observable phenotype upon deletion, suggesting either that the cell can 
fully compensate for their absence or that they have specific roles not tested by our stressors. 
These experiments allowed for the novel identification of specific functional roles for J 
proteins that had only been minimally characterized previously. The dataset also supports 
an appreciation for the complexity of the J protein network and its involvement in a wide 
range of crucial cellular functions. 
 
In Chapter 3, I describe a more mechanistic approach to understanding chaperone activities, 
both alone and in concert. I developed a peptide microarray platform in our lab in order to 
simultaneously measure many chaperone-substrate interactions. Peptide microarrays are 
particularly useful to study chaperone interactions as chaperones generally bind unfolded 
proteins, of which isolated peptides are a reasonably good mimic. I first used this technique 
to ask how chaperones converge on the substrates firefly luciferase and human tau. 
Extensive work has been done to characterize the activity of chaperones on these substrates: 
Hsp70 and co-chaperones can refold luciferase in vitro and in vivo, while many chaperones 
reduce tau aggregation and toxicity. However, the mechanistic details of these processes 
have proven challenging to untangle. For example, it is unknown why the human J protein, 
DNAJA2, is competent to catalyze luciferase refolding by Hsc70, while its close homologue 
DNAJA1 is not. Our data suggests that it is not a difference of luciferase binding sites for 
these J proteins that leads to the disparity, as originally hypothesized, but rather the ability 
of Hsc70 to stimulate binding of DNAJA2 to a β-sheet located between the two domains of 
luciferase. This finding suggests a new model of luciferase refolding by Hsc70 and a J 
protein. It is known that a J protein must first bind luciferase and recruit Hsc70, not vice 
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versa [1]. Our data suggests that when DNAJA2 recruits Hsc70, Hsc70 in turn stabilizes the 
interaction of DNAJA2 with a particular site and that this reciprocal cooperativity is what 
allows for productive luciferase refolding. This finding is reminiscent of the cooperative 
inhibition of a transcription factor, σ32, by bacterial chaperones. It has been found that 
simultaneous binding of E. coli DnaK and DnaJ to σ32 is required for effective inhibition, 
that DnaK specifically destabilizes a region of σ32 to make it available for DnaJ binding, and 
that DnaJ stimulation of DnaK ATPase activity is optimal when both are bound to the 
substrate [2, 3]. Further work is required to achieve similar mechanistic understanding of 
the refolding of luciferase by chaperones, as will be discussed below. 
 
Though many chaperones have been shown to influence tau biology in both healthy and 
diseased systems, little is known about direct interactions between chaperones and tau. I 
therefore took a broad, model-generating approach to map the interaction of many 
chaperones with tau using peptide microarrays. This approach was highly fruitful and 
yielded a rich, complex dataset from which many hypotheses can be developed. A broad 
feature of this dataset was that competition between pro-stabilizing and pro-degradation 
chaperones for binding to the same sites on tau likely plays an important role in tau 
homeostasis. Additionally, chaperones may compete with kinases, microtubules, and other 
tau molecules for tau interactions, thus playing an integral role in tau biology. The 
underlying cause of lowered chaperone levels in neurodegenerative disease is unclear, but a 
major consequence appears to be the disregulation of tau, which may contribute 
significantly to the pathological cascade. For example, hyperphosphorylation of tau may be 
due in part to the loss of chaperone competition with kinases for binding to many 
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phosphorylation-rich sites on tau. Chapter 3 explores the tau binding dataset in detail and 
draws connections to what is already known about the function, modification, and 
aggregation of tau.  
 
In Chapter 4, we used the peptide microarray platform to address another question: can 
chaperones prevent amyloid formation by directly binding amyloidogenic sequences? This 
question was prompted by the observation that Hsp70 can abrogate the formation of 
amyloid fibrils comprised of steric zippers formed by peptides with widely divergent 
physicochemical properties. My co-workers, Dr. Andrea Thompson and Dr. Atta Ahmad, 
carefully designed the amyloid array to include both amyloid-forming and normal peptides 
with equivalent average physicochemical characteristics in order to test amyloidogenicity as 
a determinant of chaperone binding. Surprisingly, our experiments revealed that some 
chaperones – Hsp70s, Hsp90, DnaJ, DNAJA1/A2/B1, and CHIP – demonstrate 
preferential binding to amyloidogenic peptides, while others do not, suggesting that these 
particular chaperones – and perhaps others not tested – have evolved certain mechanism(s) 
to detect “dangerous” sequences and prevent amyloid formation. We selected ten peptides 
from this dataset for further study and evaluated their binding by the substrate binding 
domain of Hsc70 (Hsc70SBD) using two methods: fluorescence polarization (FP) and 
isothermal titration calorimetry (ITC). By FP, we found that 4 of the 5 “binders” (as 
determined by the array data) were able to compete with the insulin peptide LVEALY for 
binding to Hsc70SBD, while only 2 of 5 “non-binders” were able to compete, yielding a 70% 
confirmation rate for our array data. Similarly, using ITC I observed Hsc70SBD binding of all 
of the binders and 3 of the 5 non-binders. Interestingly, all interactions had comparable 
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affinities and were both enthalpically and entropically favorable. These results do not 
specifically identify a mechanism by which Hsc70 might preferentially identify amyloid-
forming peptides. However, they are promising and continuing work in this area may yet 
shed light on this question.   
 
5.3 Future Directions 
5.3.1 Specific roles of J proteins in S. cerevisiae and beyond 
The chemical genetics study of J proteins in S. cerevisiae suggests both specific investigation 
avenues and a general need to better understand the roles of individual J proteins in cells. 
Our data points to a role of Swa2, a J protein involved in clathrin removal from vesicles, in 
the cell’s ability to mount a cell wall integrity (CWI) reponse. An investigation into whether 
these two functions are directly connected or distinct aspects of Swa2 biology may provide 
insights into clathrin uncoating and/or the CWI pathway and the involvement of 
chaperones in these processes. Another finding that merits further investigation is the role of 
Jjj3, an iron-bearing enzyme that participates in redox processes, as a redox partner for a 
wide array of pathways beyond its originally identified role in diphthamide synthesis. The 
finding that Apj1, a low-copy J protein that may be localized to the mitochondria, has 
synthetic lethal interactions suggests an unexpectedly important role for this J protein that 
cannot be compensated for by endogenous levels of other J proteins and deserves further 
interrogation. More broadly, this dataset highlights the diversity of J protein functions and 
their roles and relative importance to cell viability in S. cerevisiae. A growing body of 
literature supports this as a general feature of J protein co-chaperone networks in various 
organisms: they are diverse in both structure and function and have evolved to take on 
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many different roles, with the J domain functioning as a link to the Hsp70 chaperone 
machinery [4]. Our data contributes to this finding and underscores the importance of 
considering individual J proteins as unique actors within a given system, not a homogenous 
group. 
 
5.3.2 Mechanism of chaperone-mediated luciferase refolding 
Our experiments with a luciferase peptide microarray in Chapter 3 suggest that Hsc70 
stimulates DNAJA2 binding to a luciferase β-sheet comprising residues 413-439. However, 
as these results were obtained with isolated peptides, further work is necessary to determine 
whether this stimulated binding occurs in the context of full-length luciferase and whether it 
is relevant for the mechanism of luciferase refolding by these chaperones and others. One 
useful technique might be hydrogen-deuterium exchange followed by mass spectrometry to 
identify regions of unfolded luciferase protected in the presence of DNAJA2 and/or Hsc70. 
Further, enzyme-linked immunosorbent assays (ELISAs) might be used to determine 
whether DNAJA2 can bind to the identified peptide in solution and whether the presence of 
Hsc70 increases the affinity of this interaction. This experiment could also be performed 
with full-length unfolded luciferase in order to determine whether Hsc70 increases the 
affinity of DNAJA2 for the whole protein. Parallel studies would be carried out with 
DNAJA1 to control for interactions that do not promote luciferase refolding. The ELISA 
platform could also be used to test different peptides within the identified region and 
perhaps identify the minimal binding site that DNAJA2 is stimulated to bind by Hsc70. 
Using this information, point mutations of luciferase could be studied for their effect on 
Hsc70/DNAJA2-mediated refolding. Our lab has determined that other J proteins, 
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DNAJB1 and DNAJB4, are also competent to catalyze luciferase refolding (Jennifer Rauch, 
unpublished data). Therefore, if point mutants are identified that do impact the ability of 
DNAJA2 to refold luciferase, it would be informative to test whether they also affect 
refolding by these other J proteins, as well as the bacterial refolding system 
(DnaK/DnaJ/GrpE), in order to determine whether this mechanism is universal to all 
chaperone-catalyzed luciferase refolding. The insights thus gained could be expanded to 
develop hypotheses about the mechanism of chaperone refolding of other substrates.  
 
5.3.3 Testing models for tau regulation developed from peptide microarrays 
One of the major findings of the tau microarray experiments was that chaperones of 
different classes share many binding “hotspots” on tau. The logical conclusion from this  
finding is that chaperones compete with one another as part of the tau triage process. 
Further work will be needed to elucidate which interactions are actually competitive, which 
dominate in certain contexts, and 
how modification of specific 
binding sites might affect binding 
affinities and therefore tau fate 
decisions. In the final stages of 
my thesis work, I attempted to 
confirm and elaborate upon the J 
protein results. I designed a set of 
tau constructs to include or 
exclude specific binding sites 
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identified for the J proteins and Hsp70s (Figure 5.1). I then attempted to develop an ELISA 
platform to measure J protein binding to both full length tau and these constructs. 
Unfortunately, these efforts were unsuccessful, largely due to instability of the component 
proteins and the lack of reproducibility. One interesting finding of this work was that tau 
truncated at Asp25 was highly unstable, degrading into many smaller products after the 
normal purification procedure, further pointing to a key role of the N-terminus in tau 
biology, as discussed in Chapter 3. 
 
Similar work moving forward will be valuable to identify what interactions identified on the 
array are important in the context of the full tau protein. Specifically, competition between 
pro-stabilizing (BAG1, FKBP51) and pro-degradation (BAG2, FKBP52, UbcH5, Ube2w, 
CHIP) chaperones for binding to full length tau and shorter constructs will be informative. 
Additionally, the effect of tau modifications, such as phosphorylation and FDTP-17 linked 
mutations, on chaperone interactions should be explored in order to understand how 
chaperone-tau contacts may be modified in disease contexts and the role this may have in 
pathology. Specifically, the influence of MARK phosphorylation at Ser356 on 
UbcH5/CHIP ubiquitination of tau, especially at Lys353, may explain the resistance of 
MARK-phosphorylated tau to proteasomal degradation. 
 
Two specific “hotspots” that bear further investigation are the N-terminus and the 
polyproline helix/phosphorylation-rich site in the proline rich domain. As described in 
Chapter 3, the N-terminus has been found to have at least two effects in neurons: inhibition 
of anterograde fast axonal transport (FAT) and induction of exitotoxicity. As multiple 
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chaperones were found to bind the N-terminus, the effect of these chaperones (all four J 
proteins, Hsp72, BAG1, FKBP51, Ube2w, and UbcH5) on FAT inhibition and 
excitotoxicity should be explored. Additionally, the ability of these chaperones to bind N-
terminally cleaved tau (at Asp13 or Asp25, the two caspase cleavage sites identified in this 
region) should be tested to understand how chaperone interactions with tau may be affected 
by N-terminal cleavage events during disease progression. Also, due to the involvement of 
the N-terminus of tau in its conformational dynamics, it may be informative to use NMR 
and FRET to explore the effect of chaperones on the occupation of different conformational 
states of tau, particularly in the presence of different phosphorylation patterns. The 
polyproline helix immediately upstream of the repeat domain is another intriguing site of 
interest that emerged from this dataset. It is already known that Pin-1, a peptidyl-prolyl 
isomerase, interacts with tau at this site and influences the affinity of tau for microtubules. It 
appears that other chaperones may also use this site to regulate tau’s contacts and functions. 
Further experiments using point mutations or deletions are necessary to identify what 
feature(s) of this region are important for chaperone binding, such as the polyproline helix, 
the PXXP motif, or the many phosphorylated residues within this peptide. The influence of 
phosphorylation of these residues on chaperone interactions may also provide useful 
insights.  
 
It is likely that the tau array dataset represents a maximum set of possible interactions, and 
further work will be necessary to identify what interactions play important roles in tau 
biology in both healthy and diseased systems. Experiments carried out based on this dataset 
will likely lead to the discovery of even more interesting aspects of chaperone-tau 
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interactions. A better understanding of this system may eventually lead to more rationally 
targeted therapies for tauopathies.  
 
5.3.4  Understanding chaperone recognition of amyloidogenic sequences 
Current work is in progress in collaboration with the lab of David Eisenberg to further 
explore the mechanism by which chaperones, particularly Hsc70, may recognize 
amyloidogenic peptides preferentially, as suggested by our peptide microarray data. We are 
exploring the possibility that Hsc70 could interdigitate its own sidechains with those of an 
amyloidogenic peptide, thereby forming a heterosteric zipper and preventing the formation 
of homosteric zippers and therefore amyloid fibrils. The Eisenberg lab is computationally 
assessing the ability of the Hsc70 substrate binding pocket to form heterosteric zippers with 
all of the peptides included on the amyloid array. They are also attempting to co-crystallize 
amyloidogenic peptides with the Hsc70SBD in the hopes of obtaining structural information 
about such an interaction, which has yet to be achieved. In our lab, Dr. Atta Ahmad has 
developed an Hsc70SBD construct that can be used to map the binding site of peptide 
substrates. He has successfully observed the interaction of LVEALY with the canonical 
substrate binding groove in the SBD. He is going to investigate the binding of other 
amyloidogenic peptides that were observed to bind by ITC, such as VQIVYK. He will also 
investigate the possibility of multiple binding sites on the SBD using peptides that were 
unable to compete with LVEALY but did bind by ITC, such as KSNFLN. The finding that 
Hsc70 and other chaperones can preferentially bind amyloid-forming sequences is a highly 
intriguing one and may point to a fundamental mechanism of cellular protection that is 
somehow lost in the course of diseases of protein misfolding. Further work to understand 
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this mechanism may prove vital to understanding the underlying pathology of these 
diseases. 
 
5.4 Therapeutic Perspective 
The insights gained through this work about chaperone interactions with tau and 
amyloidgenic peptides suggest that chaperone-substrate or chaperone-chaperone 
interactions may constitute viable therapeutic targets, but only when we have developed a 
much more detailed understanding of chaperone networks and their roles in disease. Based 
on our evidence from the peptide microarray platform, chaperone-tau interactions seem to 
be an integral part of the complex and subtle system of tau regulation. Further work will 
expand our understanding of the role of each specific interaction. With this knowledge in 
hand, we can identify protein-protein contacts that may be beneficial to inhibit, or even 
promote, using small molecules. Alternatively, developing an understanding of how relative 
chaperone levels influence tau regulation may allow us to productively alter specific 
chaperone expression levels in order to change the fate of tau. For example, the finding that 
Hsp72 levels are unexpectedly low in the highly stressed environment of AD suggests that 
promoting expression of Hsp72, which consigns tau for proteasomal degradation, may be a 
productive approach. Overall, it seems clear that chaperones are intimately involved in 
many disease processes, and further work to understand their roles in pathology, either 
through gain or loss of function, will bring us closer to developing effective therapies for 
some of the most challenging and destructive diseases affecting society.  
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5.5 Concluding Thoughts 
With the work presented in this thesis, I attempted to advance our understanding of 
chaperone networks by developing complex datasets that provide evidence for many 
models. These datasets will serve as valuable starting points for future projects that in turn 
lead to a deeper understanding of how chaperone networks function. It is my hope that such 
work will allow for better characterization of the pathology of protein misfolding diseases, 
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